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ABSTRACT
Treatment with second generation antipsychotics (SGAs), particularly clozapine and
olanzapine, is associated with severe obesity side-effects. Histamine H1 receptor
(H1R) antagonism has been identified as a main cause of SGA-induced obesity, but
its molecular mechanisms remain unclear. The hypothalamus and brainstem dorsal
vagal complex (DVC) are well-documented in the regulation of food intake and body
weight. Using an established olanzapine-induced obesity rat model, this study
investigated the role of brain histaminergic system and its associated AMP-activated
protein kinase (AMPK) signaling in the hypothalamus and DVC at different stages
(early acceleration, middle new equilibrium, and late heavy weight maintenance) of
olanzapine-induced obesity.

Firstly, I studied the effect of olanzapine on key components of the histaminergic
system, histidine decarboxylase (HDC), H1R and H3R, in the brain at different stages
of olanzapine-induced obesity. Female rats were treated orally with olanzapine (1
mg/kg, tid, 8-hourly) for 8, 16 and 36 days to represent the three stages of olanzapineinduced obesity. At the early stage, olanzapine increased the hypothalamic HDC
mRNA expression and H1R binding in the arcuate nucleus (Arc) and ventromedial
hypothalamus (VMH). HDC mRNA and Arc H1R binding positively correlated with
feeding efficiency and weight gain, contributing to hyperphagia and rapid weight
gain. At the middle and late stage, olanzapine increased H1R binding in the Arc,
VMH and DVC. Changes in H1R binding positively correlated with weight gain
indicated their importance in chronic olanzapine-induced obesity. Olanzapine tended
viii

to decrease Arc H3R binding at the late stage. The negative correlation between H3R
binding and weight gain suggests that chronic olanzapine treatment causes obesity
also via indirectly affecting the H3R. The data suggests a time-dependent role of
histaminergic system in different stages of olanzapine-induced obesity.

Having known the importance of H1R in all the three stages of olanzapine-induced
obesity, my project studied how the brain mechanisms of H1R underlie each stage of
obesity development. The time-dependent effects of olanzapine on the hypothalamic
and DVC H1R-AMPK signaling were examined. In the hypothalamus, at the early
stage, when the rats were hyperphagic, olanzapine increased the H1R mRNA and
phospho-AMPK (pAMPK) expression, in which pAMPK positively correlated with
H1R mRNA and food intake. At the middle stage, when the rats were no longer
hyperphagic, the changes in H1R-AMPK signaling vanished. At the late stage,
olanzapine increased H1R mRNA but decreased pAMPK expression， which were
positively and negatively correlated with weight gain, respectively. In the DVC,
olanzapine activated AMPK signaling only at the early stage of obesity development.
The pAMPK/AMPK ratio, an indicator of AMPK activity, was positively correlated
with feeding efficiency and weight gain. DVC pAMPK was positively correlated with
the H1R expression. These data suggest a time-dependent role of the hypothalamic
and DVC H1R-AMPK signaling in olanzapine-induced obesity development.
Olanzapine activates AMPK by blocking the H1Rs and causing hyperphagia in the
acute phase. This was supported by the further finding that an H1R agonist, 2-(3trifluoromethylphenyl) histamine, dose-dependently inhibited olanzapine-induced
ix

hyperphagia and AMPK activation in the mediobasal hypothalamus (MBH) and DVC.
As treatment was prolonged, the chronic blockade of H1R may contribute to
olanzapine-induced decreased energy expenditure and heavy weight maintenance.
However, AMPK acts as an energy sensor and negatively responds to the positive
energy balance induced by olanzapine.

Since olanzapine-induced changes in food intake and AMPK occur in the early stage
of obesity development, the acute effect of olanzapine on central H1R-AMPK
signaling was examined. Rats received intramuscular injection of olanzapine (1mg/kg,
tid) for one and 9 injections (3 days). Olanzapine led to hyperphagia after 9 injections.
Olanzapine immediately activated the AMPK signaling in the MBH and DVC by
blocking the H1Rs. This activation of AMPK continued after 9 injections. These
findings suggest that a sustained AMPK activation via H1R blockade from the first
treatment is required for olanzapine-induced hyperphagia.

Together, the findings reveal that the time-dependent alterations of HDC, H1R and
H3R induced by olanzapine may largely contribtue to the progressive development of
obesity. Olanzapine activated the hypothalamic and DVC AMPK signaling via the
H1R blockade, leading to hyperphagia and weight gain. With prolonged treatment, the
H1R blockade contributed to weight gain via mechanisms other than AMPK, possibly
by decreasing energy expenditure. A pharmacological treatment targeting the H1R–
AMPK signaling may be an effective treatment for the olanzapine-induced
hyperphagia associated with the development of obesity.
x

Table of Contents
CHAPTER 1：INTRODUCTION AND LITERATURE REVIEW ........................................ 1
1.1 Introduction ..................................................................................................................... 1
1.2 Literature review ............................................................................................................. 2
1.2.1 Second generation antipsychotics and obesity ......................................................... 2
1.2.2 Olanzapine and obesity............................................................................................. 3
1.2.3 Histaminergic system in food intake regulation and obesity .................................... 5
1.2.4 The role of histamine H1 receptors in SGA-induced weight gain.......................... 12
A. Potential role of hypothalamic H1 receptor-AMP-activated protein kinase signaling in
energy balance and body weight regulation .................................................................... 14
B. Intracellular mechanisms for SGA-induced weight gain associated with H1 receptor
antagonism....................................................................................................................... 19
1.2.5 A potential role of HDC and H3 receptor in SGA-induced weight gain ................ 23
1.2.6 Do the HDC, H3 receptor, H1 receptor and AMPK signaling play a different role in
the three stages of SGA-induced obesity? ....................................................................... 24
1.2.7 Conclusions ............................................................................................................ 26
1.3 Aims of the study .......................................................................................................... 28
1.3.1 General aim ............................................................................................................ 28
1.3.2 Specific aims .......................................................................................................... 28
1.3.3 Hypothesis .............................................................................................................. 29
1.3.4 Significance ............................................................................................................ 30
CHAPTER 2：TIME-DEPENDENT EFFECTS OF OLANZAPINE TREATMENT ON THE
EXPRESSION OF HDC, H1 AND H3 RECEPTOR IN THE RAT BRAIN: THE ROLES IN
OLANZAPINE-INDUCED WEIGHT GAIN ......................................................................... 31
2.1 Introduction ................................................................................................................... 31
2.2 Materials and methods................................................................................................... 33
2.2.1 Animals and housing .............................................................................................. 33
2.2.2 Olanzapine treatment .............................................................................................. 34
2.2.3 Histologic procedures ............................................................................................. 35
2.2.4 Receptor autoradiography and quantification......................................................... 36
2.2.5 Real-time quantitative PCR .................................................................................... 38
xi

2.2.6 Statistics.................................................................................................................. 39
2.3 Results ........................................................................................................................... 40
2.3.1 Food intake, weight gain, water intake and fat mass following 8, 16 and 36 days
olanzapine treatment ........................................................................................................ 40
2.3.2 The effect of olanzapine on the gene expression of the hypothalamic HDC and H3
receptor ............................................................................................................................ 41
2.3.3 The effects of olanzapine on H1 receptor binding in the brain .............................. 45
2.3.4 The effects of olanzapine on H3 receptor binding in the brain .............................. 53
2.4 Discussion ..................................................................................................................... 57
2.5 Summary ....................................................................................................................... 63
CHAPTER 3 ： HYPOTHALAMIC HISTAMINE H1 RECEPTOR-AMPK SIGNALING
TIME-DEPENDENTLY MEDIATES OLANZAPINE-INDUCED HYPERPHAGIA AND
WEIGHT GAIN IN FEMALE RATS ..................................................................................... 65
3.1 Introduction ................................................................................................................... 65
3.2 Materials and methods................................................................................................... 67
3.2.1 Animals and housing .............................................................................................. 67
The same rats and housing that were described in Chapter 2 were used in the present study.
............................................................................................................................................. 67
3.2.2 Experiment one....................................................................................................... 67
3.2.3 Experiment two ...................................................................................................... 68
3.2.4 Real-time quantitative PCR .................................................................................... 69
3.2.5 Western blot............................................................................................................ 70
3.2.6 Statistics.................................................................................................................. 71
3.3 Results ........................................................................................................................... 72
3.3.1 Hyperphagia contributed to rapid weight gain in the early stage of olanzapineinduced obesity ................................................................................................................ 72
3.3.2. Olanzapine induced time-dependent changes of hypothalamic H1 receptor-AMPK
signaling differing in the three stages of obesity development ....................................... 72
3.3.3 Histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine, attenuated
olanzapine-induced hyperphagia ..................................................................................... 78
3.3.4 FMPH treatment inhibited olanzapine-induced AMPK activation in the
hypothalamic MBH ......................................................................................................... 81
xii

3.3.5 FMPH increased the mRNA expression of CRH in the PVN in olanzapine-treated
rats ................................................................................................................................... 82
3.4 Discussion ..................................................................................................................... 87
3.5 Summary ....................................................................................................................... 92
CHAPTER 4 ： OLANZAPINE-ACTIVATED AMPK SIGNALING IN THE DVC IS
ATTENUATED BY CENTRAL H1 RECEPTOR AGONIST INJECTION IN FEMALE
RATS ....................................................................................................................................... 93
4.1 Introduction ................................................................................................................... 93
4.2 Materials and methods................................................................................................... 94
4.2.1 Animals, drugs treatment and tissue preparation.................................................... 94
4.2.2 Western blot............................................................................................................ 95
4.2.3 Statistics.................................................................................................................. 95
4.3 Results ........................................................................................................................... 96
4.3.1. Olanzapine activated the DVC AMPK signaling after 8 days but not 16 or 36 days
treatment .......................................................................................................................... 96
4.3.2. Olanzapine-induced activated DVC AMPK was inhibited by the H1 receptor
agonist in a dose-dependent manner .............................................................................. 100
4.4 Discussion ................................................................................................................... 102
4.5 Summary ..................................................................................................................... 106
CHAPTER 5 ： ACUTE OLANZAPINE TREATMENT IMMEDIATELY ACTIVATS
AMPK SIGNALING IN THE MBH AND BRAINSTEM DVC VIA BLOCKING
HISTAMINE H1 RECEPTOR .............................................................................................. 108
5.1 Introduction ................................................................................................................. 108
5.2 Martials and methods .................................................................................................. 109
5.2.1 Animals and housing ............................................................................................ 109
5.2.2 Acute olanzapine treatment and tissue dissection ................................................ 109
5.2.3 Western blot.......................................................................................................... 110
5.2.4 Statistics................................................................................................................ 110
5.3 Results ......................................................................................................................... 111
5.3.1 IM injection of olanzapine-induced food intake and weight gain ........................ 111
5.3.2 The effect of olanzapine on AMPK signaling in the MBH, PVN and brainstem
DVC............................................................................................................................... 111
xiii

5.4 Discussion ................................................................................................................... 117
5.5 Summary ..................................................................................................................... 119
CHAPTER 6：OVERALL DISCUSSION AND CONCLUSIONS .................................... 120
6.1 Overall discussion ....................................................................................................... 120
6.2 Recommendations for further research........................................................................ 125
REFERENCES ...................................................................................................................... 129
APPENDIX ONE .................................................................................................................. 139
APPENDIX TWO ................................................................................................................. 152
APPENDIX THREE ............................................................................................................. 165

xiv

List of Figures
Figure 1.1 The hypothalamic histamine synthesis and release, and its role in
regulating food intake…………………………………………………………….…..8
Figure 1.2 Possible neural pathways of SGA-induced weight gain by H1 receptor
antagonism…………………………………………………………………..…….…17
Figure 1.3 Potential role of hypothalamic H1 receptor-AMPK signaling in SGAinduced hyperphagia……………………………………………………….……...….21
Figure 2.1 Effects of olanzapine (1 mg/kg, tid) on 48 h food intake (A), weight gain
(B) and 48 h water intake (C)…………...………………………………………...….42
Figure 2.2 Effects of olanzapine (1 mg/kg, tid) treatment on the mRNA expression of
HDC (A, B, C) and the H3 receptor (D, E, F) in the rat hypothalamus after 8-, 16- and
36-day treatments ……………………………………………………………..……..43
Figure 2.3 Representative autoradiograms showing H1 receptor binding in the rat
hypothalamus.....………………….………………………………….………………46
Figure 2.4 The effect of olanzapine on the H1 receptor expression (nCi/mg tissue) in
the hypothalamic Arc, PVN, VMH, DMH, and LHA, and brainstem DVC after 8 (A,
B), 16 (C, D), and 36-day (E, F) treatments ……………………………………..…..48
Figure 2.5 Map (A) and example (B) of H1 receptor binding in the hypothalamus,
and examples of H1 receptor binding in the hypothalamus after 8 (C, D), 16 (E, F),
and 36-day (G, H) olanzapine or vehicle treatments……………………..………….49
Figure 2.6 Map (A) and example (B) of H1 receptor binding in the DVC, and
examples of H1 receptor binding in the brainstem DVC for 8 (C, D), 16 (E, F), and
xv

36-day (G, H) olanzapine or vehicle treatments ………………………………..……50
Figure 2.7 Representative autoradiograms showing H3 receptor binding in the rat
hypothalamus……………………………………………………………………….. 54
Figure 2.8 The effect of olanzapine on the H3 receptor expression (nCi/mg tissue) in
the hypothalamic Arc, PVN, VMH, DMH, and LHA after 8 (A), 16 (B), and 36-day
(C) treatments.………………………………………………………………….……55
Figure 3.1 Effects of olanzapine on the gene expressions of hypothalamic H1
receptor-AMPK signaling after 8- (A, early stage), 16- (B, middle stage) and 36-day
(C, late stage) olanzapine treatments…………………………………………..….….74
Figure 3.2 Effects of olanzapine on the protein expressions of hypothalamic H1
receptor-AMPK signaling after 8- (early stage), 16- (middle stage) and 36-day (late
stage) olanzapine treatments …………………………………………………….…..76
Figure 3.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on olanzapine-induced increased food
intake …………………………..………………………………………….…..……..80
Figure 3.4 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on the hypothalamic AMPK signaling in
olanzapine or vehicle-treated rats ……………………………………………..…….84
Figure 3.5 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on mRNA expressions of: CRH in the
PVN (A), leptin receptor in the MBH (B), orexin-A in the LHA (C), NPY (D), and
AgRP (E) in the MBH in either olanzapine or vehicle-treated rats…………………..86
xvi

Figure 4.1 Effects of olanzapine on the protein expressions of DVC AMPK signaling
and the H1 receptor after 8 days olanzapine treatment ……………………….……..97
Figure 4.2 Effects of olanzapine on the protein expressions of DVC AMPK signaling
and the H1 receptor after 16 and 36 days olanzapine treatment ………….…..……..99
Figure 4.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on DVC AMPK signaling …………..101
Figure 5.1 Food intake, weight gain and feeding efficiency in rats receiving IM
injections of olanzapine (1mg/kg, tid) or water (control) for one injection (A) and 9
injections ( 3 days, B, C, D) ……………………………………………….……….112
Figure 5.2 Effects of IM injection of olanzapine (one injection) on the protein
expressions

of

key

components

of

hypothalamic

H1

receptor-AMPK

signaling ……………………………………………….……………….…..………113
Figure 5.3 Effects of IM injection of olanzapine (9 injections) on the protein
expressions

of

key

components

of

hypothalamic

H1

receptor-AMPK

signaling ……………………………………………………………………………116
Figure 6.1 A potential mechanism of histaminergic system and its associated AMPK
signaling in different stages of olanzapine-induced obesity ….................................127

xvii

List of Tables
Table 2.1 Body weight gain and fat mass of rats treated with olanzapine or vehicle for
8, 16 and 36 days ……………………..…………….…..……………………………44
Table 2.2 Correlations within the hypothalamic H1 receptor binding density, feeding
efficiency and cumulative weight gain during different terms of olanzapine treatment
(8, 16 and 36 days) ……………………….……………………………………….....51
Table 2.2 Specific [3H] pyrilamine binding (nCi/mg tissue; mean ± SEM) to H1
receptors in different brain regions following different terms (8, 16, and 36 days) of
olanzapine or vehicle treatment …………………………………………….…..…..52
Table 2.4 Specific [3H]NAMH binding (nCi/mg tissue; mean ± SEM) to H3 receptors
in different brain regions following different terms (8, 16, and 36 days) of olanzapine
or vehicle treatment ………………………………………….…………..…………..56
Table 3.1 Correlations within the hypothalamic H1 receptor mRNA, pAMPKα and
pACCα protein expression, food intake and weight gain during the three stages of
olanzapine-induced obesity ………………………………...…………………..……77
Table 3.2 Correlations within the MBH pAMPKα and pACCα protein expression and
food intake during FMPH and olanzapine treatment …………………………..……85
Table 5.1 Correlations within the pAMPK/AMPK in the MBH and DVC, feeding
efficiency and cumulative weight gain after rats received 9 injections of olanzapine or
water (3 days)……………………………………………………………………….115

xviii

List of Abbreviations
AcbC

Accumbens Nucleus, Core

ACC

Acetyl-CoA Carboxylase

AgRP

Agouti-Related Peptide

AMPK

AMP-Activated Protein Kinase

AP

Area Postrema

Arc

Arcuate Nucleus

BAT

Brown Adipose Tissue

BBMI

Baseline Body Mass Index

Cg

Cingulate Cortex

CNS

Central Nervous System

CPT1

Carnitine Palmitoyltransferase 1

CPu

Caudate Putamen

CRH

Corticotrophin-Releasing Hormone

CVD

Cardiovascular Disease

DMH

Dorsomedial Hypothalamic Nucleus

DMV

Dorsal Motor Nucleus of the Vagus

DVC

Dorsal Vagal Complex

EPS

Extrapyramidal Side Effects

GPCR

G-Protein-Coupled Receptor

H1R

Histamine H1 Receptor

H3R

Histamine H3 Receptor
xix

HDC

Histidine Decarboxylase

HIP

Hippocampus

LHA

Lateral Hypothalamic Area

M1

Primary Motor Cortex

MBH

Mediobasal Hypothalamus

mRNA

Messenger Ribonucleic Acid

NPY

Neuropeptide Y

NTS

Nucleus of the Solitary Tract

PFC

Prefrontal Cortex

PGC-1α

Peroxisome Proliferator Activated Coactivator 1α

PVN

Paraventricular Hypothalamic Nucleus

POMC

Pro-opiomelanocortin

PVN

Paraventricular Nucleus

SD

Sprague Dawley

SGAs

Second Generation Antipsychotics

Tid

Three Times Daily

TM

Tuberomammillary Nucleus

UCP-1

Uncoupling protein 1

VMH

Ventromedial Hypothalamus

xx

CHAPTER 1

INTRODUCTION AND LITERATURE REVIEW

1.1 Introduction
Schizophrenia is a chronic and complex mental illness that has a prevalence of
approximately 1% world-wide (Tandon et al., 2008). Antipsychotic medication is a
key pharmacotherapy in the clinic to treat schizophrenia, bipolar disorder and a
variety of other psychiatric disorders. Compared with the first generation
antipsychotics, second generation antipsychotics (SGAs) such as olanzapine,
clozapine, quetiapine, risperidone and ziprasidone are effective in treating multiple
aspects of schizophrenia (Keefe et al., 2006, Leucht et al., 2009). Additionally, SGAs
have a lower risk of extrapyramidal side effects (EPS) and tardive dyskinesia (Peluso
et al., 2012). It has been reported that in recent years the overall SGA prescription has
largely increased in adults, children and adolescents for a number of psychiatric
disorders (Parsons et al., 2009, Correll et al., 2011, Lett et al., 2012). Unfortunately,
these medications are associated with dramatic weight gain/obesity. This weight gain
induced by SGAs is a significant factor for patient noncompliance and causes severe
co-morbidities including dyslipidemia, type II diabetes, cardiovascular diseases
(CVDs) and stroke (Parsons et al., 2009, Rummel-Kluge et al., 2010, Correll et al.,
2011, Lett et al., 2012). These issues highlight the urgency of understanding the
1

mechanisms underlying SGA-induced weight gain/obesity. In the last few years,
multiple contributors have been reported to be involved in antipsychotic-induced
weight gain. For example, SGAs directly interact with a range of neurotransmitter
receptors that are involved in energy homeostasis, such as histaminergic H1,
serotoninergic 2A and 2C, adrenergic α, muscarinic M3 and dopaminergic D2
receptors (Coccurello and Moles, 2010, Deng et al., 2010, Roerig et al., 2011).
Notably, the antagonistic effect on histamine H1 receptors has been identified as a
primary contributor of SGA-induced obesity, particularly with the use of olanzapine
and clozapine (Matsui-Sakata et al., 2005, Nasrallah, 2008). However, the exact
neural mechanisms that promote SGA-induced weight gain are not fully understood.
Therefore, the present PhD study investigated the role of the histaminergic system
with a focus on central H1 receptor antagonism and its related molecular pathways in
weight gain induced by olanzapine in a female rat model. An improved understanding
of the mechanisms underlying the H1 receptor antagonism in olanzapine-induced
weight gain could help in designing a better treatment strategy for preventing and
treating SGA-induced weight gain and its associated life-threatening diseases such as
type 2 diabetes and cardiovascular disease.

1.2 Literature review

1.2.1 Second generation antipsychotics and obesity
Schizophrenia affects approximately 1 in 100 people world-wide, and can emerge
during adolescence and young adulthood (Hollis, 2000, Tandon et al., 2008).
2

Schizophrenia is characterized by positive symptoms such as hallucinations, delusion
and thought disturbances; negative symptoms such as poverty of speech, anhedonia
and apathy; and cognitive symptoms associated with memory, attention process and
executive functioning (Kurtz et al., 2001). Schizophrenia shortens the lifespan and
significantly impairs social and vocational function of patients (Tandon et al., 2010).

Antipsychotic medication is a primary method used to treat schizophrenia. First
generation antipsychotics (FGAs), such as haloperidol, are effective in treating
positive symptoms of schizophrenia but have reduced efficacy to reduce negative and
cognitive symptoms. Additionally, FGAs are associated with serious side-effects such
as extrapyramidal symptoms like tardive dyskinesia and Parkinsonism. SGAs, such as
olanzapine and risperidone, are widely used in the clinic. Compared with FGAs,
SGAs are effective in treating multiple aspects of schizophrenia while causing fewer
EPS. However, the set-back is that SGAs are associated with a high risk of inducing
metabolic disorders such as weight gain, subcutaneous and intra-abdominal obesity,
reduced physical activity and dyslipidemia (Archie et al., 2003, Nasrallah, 2008,
Parsons et al., 2009).

1.2.2 Olanzapine and obesity
Olanzapine is one of the most widely used SGAs to treat schizophrenia (Mond et al.,
2003), due to its efficacy to treat multiple aspects of schizophrenia and greater
tolerability (Maciulis et al., 2004, Sikich et al., 2008). In clinical trials, olanzapine
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also has a greater efficacy to treat the positive symptoms of schizophrenia compared
to other SGAs including quetiapine, ziprasidone and risperidone (Leucht et al., 2009).
However, excepting clozapine, olanzapine is associated with the highest risk for
weight gain, followed by quetiapine and risperidone, and rarely with aripiprazole and
ziprasidone, in both children and adults (Parsons et al., 2009, Almandil et al., 2013). A
large-scale study (Clinical Antipsychotic Trials of Intervention Effectiveness study,
CATIE study) reported that more than one third of olanzapine-treated patients gained
7% or more body weight from baseline in one year (McEvoy et al., 2005). Patients
experienced mean weight gain, ranging from 6.8 to 11.8 kg after standard doses of
olanzapine treatment for 1 year (Nasrallah, 2008). Olanzapine treatment induced a
weight gain of 7.2 kg (11.1%) for the first 12 weeks treatment in adolescents.
Moreover, clinical data revealed olanzapine-induced weight gain was largely
associated patients‘ baseline body mass index (BBMI). The percentage of patients
gaining ≥ 7% baseline weight gain was significantly larger in underweight/normal
patients than obese patients (Bushe et al., 2013). Patients with lower BBMI also had a
larger mean weight gain (Kinon et al., 2001). It has been reported that weight gain
may lead to diabetes, hypertension, CVDs (Grundy, 2004, Zhang et al., 2004,
Després, 2006) and patients‘ non-compliance as well as inducing a greater risk of
morbidity (Allison et al., 1999). Therefore, it is important to understand the
mechanisms of olanzapine-induced weight gain, in order to prevent and treat
olanzapine-induced weight gain as well as produce new antipsychotics with lower
weight gain liability.
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In recent years, multiple contributors have been identified that are involved in
antipsychotic-induced weight gain, such as the histaminergic H1 and H3, serotonin
2C, and dopaminergic D2, muscarinic M3, and adrenergic α receptors (Coccurello and
Moles, 2010, Deng et al., 2010, Roerig et al., 2011). Neuropeptide Y (NPY), Proopiomelanocortin (POMC) (Ferno et al., 2011) and central ghrelin signaling (Zhang et
al., 2014a) have also been reported to be involved in olanzapine-induced obesity.
However, the exact neural mechanisms that promote SGA-induced weight gain are
not fully understood. Central H1 receptor antagonism by SGAs (in particular with the
use of olanzapine and clozapine) has been identified as one of the major factors that
cause weight gain and obesity. However, how olanzapine modulates the central
histamine system, and the related pathways of H1 receptor in olanzapine-induced
weight gain are not fully understood.

Part of this sections were published in He, M., Deng, C., Huang, X.F., 2013. The role
of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain. CNS
Drugs 27, 423-434.

1.2.3 Histaminergic system in food intake regulation and obesity
1.2.3.1 The role of hypothalamus and brainstem dorsal vagal complex in the
control of energy homeostasis
The hypothalamus and brainstem dorsal vagal complex (DVC) have a wellestablished role in the regulation of food intake and energy homeostasis (Broberger
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and Hokfelt, 2001, Berthoud, 2002, Morton et al., 2006). An imbalance of the systems
in the hypothalamus and DVC that mediate food intake can lead to obesity and other
metabolic disorders (Pinkney et al., 2002, Weston-Green et al., 2008).

The hypothalamus is comprised of several important regions, regulating energy
homeostasis by integrating the hormonal, nutritional and neuronal signals.
Particularly, the mediobasal hypothalamus (MBH, namely the arcuate nucleus (Arc)
and ventromedial nucleus (VMH)) is a major site for food intake and body weight
regulation (Lu et al., 2013). It has been reported that rats with lesion of MBH (Arc
and VMH) have increased food intake and weight gain (Thornton et al., 1991, Choi et
al., 1999). Within the MBH, the Arc is located at the base of the third ventricle above
the median eminence and is a major hub to converge central and peripheral signals of
energy status (Dalvi et al., 2011). The Arc contains neurons referred to as ―first order‖
neurons (such as NPY/ Agouti-related peptide neurons (AgRP)), that project to the
―second order‖ neurons in other hypothalamic regions such as the paraventricular
nucleus (PVN), VMH and lateral hypothalamic area (LHA) (Dalvi et al., 2011). The
VMH neurons project to the PVN, LHA and brainstem DVC in body weight
regulation (Lage et al., 2008). The PVN lies adjacent to the third ventricle. The PVN
can receive projections from the MBH, and also sends projections to the brainstem
DVC, to control the appetite and autonomic functions (Blevins and Baskin, 2010).
Besides the MBH and PVN, the dorsal hypothalamic nucleus (DMH) and LHA also
regulate food intake. In contrast to MBH and PVN lesions, DMH and LHA lesion
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results in a reduced body weight gain (Lytle and Campbell, 1975, Mosier et al., 1993).
It has been reported that the DMH neurons can project to the PVN and receive
afferents from DVC (Horst and Luiten, 1986). LHA contains neurons that project to
the DVC and is associated with hunger regulation (Blevins and Baskin, 2010).

The DVC, which is located at the caudal brainstem, comprises the nucleus of the
tractus solitarius (NTS), dorsal motor nucleus of the vagus (DMV), and area postrema
(AP). DVC is well-known for mediating appetite by responding to satiety signals. The
NTS not only receives ascending projections about energy status from the gut, but
also receives descending projections from most hypothalamic regions including the
MBH and PVN to regulate food intake (Schwartz, 2006, Blevins and Baskin, 2010).
The DMV, located ventral to the NTS and containing primary efferents to regulate the
gut, is involved in mediating food intake (Cone, 2005, Zhang et al., 2013b). The AP is
located on the dorsal surface of the medulla oblongata. It has been reported that lesion
of AP causes reductions in food intake and body weight in rats (Hyde and Miselis,
1983).

1.2.3.2 The role of histamine and H1 receptors in food intake and body weight
regulation
A. Hypothalamic H1 receptor in food intake and body weight regulation
In both humans and animals, histaminergic fibres are extensively distributed in the
central nervous system (CNS) and hold a key position in brain homeostatic regulation
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such as feeding rhythms, energy metabolism, the sleep–waking cycle, and learning
(Masaki and Yoshimatsu, 2006, Haas et al., 2008). Histaminergic neurons originating
from the tuberomammillary nucleus (TM) of the hypothalamus project to many brain
areas including the structures within the hypothalamus (Masaki and Yoshimatsu, 2006,
Haas et al., 2008). Histamine is synthesized by the oxidative decarboxylation of
histidine by the enzyme histidine decarboxylase (HDC) (Haas et al., 2008). Histamine
is stored in axon varicosities or released into the synaptic cleft (Haas et al., 2008).
Both the synthesis and release of histamine are controlled by the presynaptic H3
receptors (Figure 1.1).

Figure 1.1 The hypothalamic histamine synthesis and release, and its role in
regulating food intake. Hypothalamic histamine is synthesised by the oxidative
decarboxylation of histidine by the enzyme HDC (1), Histamine is stored in axon
varicosities or released into the synaptic cleft (2). Both the synthesis and release of
histamine are controlled by the presynaptic H3 receptors (3). Histamine regulates food
intake via acting on the post-synaptic H1 receptors (4). FI: food intake; HA:
histamine; HDC: histidine decarboxylase; BW: body weight.
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Increased histamine signaling in the hypothalamus contributes to reductions in food
intake and body weight in cats (Clineschmidt and Lotti, 1973), rats (Itowi et al., 1988,
Lecklin et al., 1998), and mice (Masaki et al., 2001, Masaki et al., 2003). Histaminedeficiency mice (HDC deficient mice) exhibit obesity, increased visceral adiposity,
hyperleptinemia and hyperinsulinemia, and are predominantly obesity prone when fed
a high-fat diet (Fulop et al., 2003, Jorgensen et al., 2006). To date, four histamine
receptors (H1-H4) have been found in mammals, in which the H1 receptor is the most
well-documented in feeding and body weight regulation (Masaki and Yoshimatsu,
2006). In H1 receptor knock-out mice, mature-onset obesity accompanied by
hyperphagia and increased visceral adiposity have been found (Masaki et al., 2004)
while in humans, prescription of H1 antihistamine medicines (blocking H1 receptors)
is also associated with increased body weight (Silverstone and Schuyler, 1975, Saleh
et al., 1979, Chervinsky et al., 1994) and body mass index, according to the National
Health and Nutrition Examination Survey (NHANES) (Ratliff et al., 2010). A number
of studies have shown that histamine suppresses food intake through H1 receptors in
the VMH and PVN (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et al., 1989,
Ookuma et al., 1993) (Figure 1.2 A). Previous studies in rats found that food
deprivation under scheduled feeding significantly activated the neurons that express
H1 receptors in the caudal Arc (Umehara et al., 2010, Umehara et al., 2011). These
findings revealed that the Arc H1 receptors also play a role in feeding regulation
(Figure 1.2A). Therefore, central histamine acts on the post-synaptic H1 receptor in
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the Arc, VMH and PVN to reduce food intake. Besides food intake, the hypothalamic
H1 receptors are also reported to be involved in energy expenditure regulation,
possibly by regulating sympathetic outflow to brown adipose tissue (BAT) to regulate
body weight (Masaki et al., 2003).

B. A potential role of the DVC H1 receptor in food intake and body weight
regulation
Histamine neurons originating from the TM also send projections to the DVC in
particular the NTS (Watanabe et al., 1984, Bhuiyan et al., 2011). H1 receptors
radioligand binding is high in the DVC (Panula et al., 1989, Lintunen et al., 1998). A
recent study in rats reported that H1 receptors are extensively co-localized with the
neuronal marker (NeuN) but not the glial cell marker (glial fibrillary acidic protein) in
the NTS, suggesting that the H1 receptors are predominantly located on neurons but
not on glial cells (Bhuiyan et al., 2011). Activation of H1 receptors in the NTS is
associated with cardiovascular homeostasis regulation in rats, which increases arterial
pressure and heart rate (Bhuiyan et al., 2011). However, the role of DVC H1 receptors
in feeding and body weight regulation is unknown (Figure 1.2A). Given the
importance of DVC in feeding regulation, it is possible that DVC H1 receptors also
play a role in food intake and body weight regulation.

1.2.3.3 The role of HDC in body weight regulation
HDC exists in most mammalian tissues and is highly expressed in the posterior
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hypothalamus where histamine is produced (Krusong et al., 2011). HDC plays an
ensential role in food intake and body weight regulation. HDC knock-out mice are
accompanied by increased body weight and epididymal adipose tissue and an
increased

plasma

leptin

concentration

(Yoshimatsu

et

al.,

2002).

An

intracerebroventricular (icv) injection of histidine, a precursor of histamine,
significantly increases the hypothalamic HDC activity and histamine concentration,
and decreases food intake and weight gain in rodents (Yoshimatsu et al., 2002). On
the other hand, icv administration of the HDC inhibitor, alpha-fluoromethylhistidine
(FMH), blocks histidine-induced elevation of histamine synthesis, and attenuates the
suppressive effect of histidine on food intake (Yoshimatsu et al., 2002).

1.2.3.4 The role of H3 receptor in body weight regulation
H3 receptors are highly expressed in the hypothalamus, especially in the TM (Pillot et
al., 2002). The synthesis and release of histamine are regulated by pre-synaptic H3
autoreceptors (Arrang et al., 1987, Gomez-Ramirez et al., 2002) (Figure 1.1). H3
receptor also plays a role in regulating food intake, energy expenditure and body
weight. Several studies in animal models have demonstrated that blockade of the H3
receptor decreases food intake (Itoh et al., 1998, Itoh et al., 1999, Attoub et al., 2001,
Hancock and Brune, 2005, Malmlof et al., 2005) while activation of H3 receptors by
immepip increases food intake (Chiba et al., 2009). H3 receptor knock-out mice are
associated with hyperphagia, increased weight gain, reduced energy expenditure,
decreased plasma leptin level and increased histamine turnover in the hypothalamus
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(Takahashi et al., 2002). Previous studies show that the H3 receptor mediates food
intake and body weight partly by regulating histamine synthesis and release (Malmlof
et al., 2005, Ishizuka et al., 2008). Additionally, treatment with an H3 receptor
antagonist induces hypophagia, and this effect is attenuated by H1 receptor antagonist
(Hancock and Brune, 2005). The data suggest that the H3 receptor also regulates food
intake partly through the H1 receptor. H3 receptor activation reduced histamine
synthesis and secretion (Passani et al., 2011). A reduced histamine level increased
feeding via the H1 receptors (Fukagawa et al., 1989, Ookuma et al., 1993). Therefore,
H3 receptor activation may lead to a reduced histamine level and thus compounding
feeding behaviour via the H1 receptor. However, H3 receptors are also located on
non-histaminergic neurons, working as heteroreceptors to control the neurotransmitter
release such as acetylcholine, serotonin and dopamine, which may be involved in food
intake regulation (Arrang et al., 1995, Molina-Hernandez et al., 2000, Threlfell et al.,
2004, Deng et al., 2010, Passani et al., 2011).

1.2.4 The role of histamine H1 receptors in SGA-induced weight gain
Emerging data have shown that histamine H1 receptors play an important role in
SGA-induced weight gain/obesity, as reviewed in Nasrallah (2008) and Deng et al.
(2010). Based on the data from the literature, the weight gain liability of different
SGAs is clozapine = olanzapine > quetiapine ≥ risperidone > ziprasidone =
aripiprazole (Haddad, 2005, Gentile, 2006, Nasrallah, 2008, Coccurello and Moles,
2010). The exact values of binding affinity of antipsychotics on the H1 receptor can
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vary from study to study. Overall, the affinity of SGAs for the H1 receptors is
approximately clozapine > olanzapine > quetiapine > risperidone > ziprasidone >
aripiprazole (Kroeze et al., 2003, Kim et al., 2007). A previous study which screened
17 antipsychotics to test the relationship between weight gain and their affinities for
12 neurotransmitter receptors found that antagonism of the H1 receptor is a strong
predictor for short-term antipsychotic-induced weight gain (Kroeze et al., 2003). It
was also revealed that H1 receptor occupancy is strongly correlated with SGAinduced weight gain both in clinical trials and estimated by meta-analysis (MatsuiSakata et al., 2005). Recently, studies in patients treated with antipsychotics showed a
significant association of interaction between the genetic variants of H1 receptors
(rs346074–rs346070) and BMI and obesity when comparing patients treated with high
H1 receptor affinity antipsychotics (olanzapine, clozapine and quetiapine) with those
treated with lower H1 receptor affinity antipsychotics (such as aripiprazole) (Vehof et
al., 2011). However, earlier studies also reported no relationship between other H1
receptor variants and clozapine-induced weight gain (Basile et al., 2001, Hong et al.,
2002). Additionally, in a rat model, H1 receptor expression in the hypothalamic Arc
and VMH was altered by olanzapine (1.5mg/kg/day, oral), but not haloperidol
(0.3mg/kg/day, oral) or aripiprazole (2.25 mg/kg/day, oral). In addition, the mRNA
expression of H1 receptor in the Arc is significantly negatively correlated with body
weight gain and feeding efficiency (Han et al., 2008). These findings show that
blockade of H1 receptors largely contributes to SGA-induced obesity. However,
another study also suggested that the antagonism of serotonin 2C receptors but not H1
13

receptors in the presence of dopamine D2 receptor antagonism contributes to
olanzapine-induced obesity, since co-treatment of haloperidol (D2 receptor
antagonist) with either SB 243213 (serotonin 2C receptor antagonist) or SB
243213+mepyramine (H1 receptor antagonist), but not mepyramine alone, mimicked
an olanzapine-like increase in body weight in rats (Kirk et al., 2009). On the other
hand, activation of H1 receptors can attenuate SGA-induced weight gain. For
example, in both schizophrenia patients and animal models, co-treatment of
olanzapine and betahistine, an H1 receptor agonist and H3 receptor antagonist,
significantly reduced olanzapine-induced weight gain (Poyurovsky et al., 2005, Deng
et al., 2012). A recent clinical study (Poyurovsky et al., 2012) demonstrates that cotreatment of betahistine and reboxetine (a norepinephrine reuptake inhibitor) with
olanzapine for 6 weeks in patients significantly attenuated olanzapine-induced weight
gain, and the attenuating effect of betahistine+reboxetine was two-fold larger than the
reboxetine-only treatment reported in a previous study (Poyurovsky et al., 2007).

1.2.4.1 Intracellular mechanisms for SGA-induced weight gain by H1 receptor
antagonism

A. Potential role of hypothalamic H1 receptor-AMP-activated protein kinase
signaling in energy balance and body weight regulation
AMP-activated protein kinase (AMPK) is a well-known crucial cellular energy
sensor, which can modulate energy homeostasis in the whole body (Hardie et al.,
2012). Activation of AMPK stimulates catabolic pathways such as fatty acid
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oxidation, mitochondrial biogenesis and glycolysis, while inhibiting anabolic
pathways such as fatty acid synthesis, gluconeogenesis, and glycogen (Lim et al.,
2010). In the hypothalamus, AMPK is highly expressed in multiple regions including
the Arc, VMH, PVN and LHA. The hypothalamic AMPK links energy metabolic
status and neurotransmitter/neuropeptides systems to regulate energy balance and
body weight (Lage et al., 2008, Lim et al., 2010, de Morentin et al., 2011). Previous
evidence revealed that AMPK may be key in H1 receptor-involved food intake
regulation. Kim et al. (2007) reported that histamine significantly inhibited AMPK
activity in hypothalamic slices; in contrast, the H1 receptor antagonist, triprolidine,
stimulated AMPK activity in both hypothalamic slices and the mouse hypothalamus.
Recently, a study on the hypothalamic GT1-1 cell line also found similar results; the
H1 receptor antagonist, chlorpheniramine, increased the protein level of phosphoAMPK (pAMPK: activated AMPK), which could be blocked by histamine (Kang et
al., 2012). A range of evidence has demonstrated that activation of hypothalamic
AMPK increases food intake and body weight, while inhibition of hypothalamic
AMPK decreases feeding and body weight (Andersson et al., 2004, Kim et al., 2004,
Minokoshi et al., 2004, Florant et al., 2010). Moreover, recent research demonstrated
that AMPK in the VMH is involved in regulating energy expenditure (Lopez et al.,
2010, Whittle et al., 2012). Activation of VMH AMPK results in a decrease in BAT
thermogenesis and weight gain (Whittle et al., 2012), while inhibition of VMH
AMPK increases the sympathetic nervous system activity and BAT thermogenesis
(Lopez et al., 2010).
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Hypothalamic AMPK can regulate fatty acid metabolism pathways in the CNS and
plays an important role in feeding regulation and energy homeostasis, although the
CNS does not use fatty acids as a primary energy source (Ronnett et al., 2006, Lage et
al., 2008). Both genetic and pharmacological modifications of the key steps of
AMPK-regulated fatty acid metabolism affect feeding and body weight (AMPKACC—Malonyl- CoA—CPT1 axis; ACC: acetyl-CoA carboxylase; CPT1: carnitine
palmitoyltransferase 1) (Kola, 2008, Lage et al., 2008). Briefly, AMPK activation by
phosphorylation directly inhibits acetyl-CoA carboxylase (ACC) activity, which is an
important enzyme that converts acetyl-CoA to malonyl-CoA. This effect results in a
decrease

in

malonyl-CoA,

which

is

an

allosteric

inhibitor

of

carnitine

palmitoyltransferase 1 (CPT1), and inhibits fatty acid synthesis. Decreased malonylCoA levels disinhibits CPT1 activity which up-regulates food intake partly by
increasing fatty acid oxidation (Kola, 2008, Lage et al., 2008).

Within the hypothalamus, the Arc, VMH and PVN are key regions for AMPK
regulating food intake and energy expenditure, and also play important roles in H1
receptor-involved food intake regulation which is already discussed (Ookuma et al.,
1989, Ookuma et al., 1993, Andersson et al., 2004, Kola, 2008, Lage et al., 2008,
Lopez et al., 2008, Umehara et al., 2010, Kohno et al., 2011). It is possible that
AMPK may act as a downstream signaling target of H1 receptors in the Arc, VMH
and PVN in food intake regulation (Figure 1.2A). To test this hypothesis, studies may
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examine whether the H1 receptor antagonist-induced hyperphagia and weight gain
could be reduced by blocking AMPK in the Arc, VMH and PVN.

Figure 1.2 Possible neural pathways of SGA-induced weight gain by H1 receptor
antagonism.
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(A) In normal conditions: histamine regulates food intake via acting on H1 receptors
in the MBH (Arc and VMH) and PVN, in which AMPK may act as a downstream
pathway (1). Histaminergic neurons also project to the DVC, which can receive
descending projections from most hypothalamic regions and control food intake (2).
(B) Proposed role of H1 receptors in SGA-induced weight gain: H1 receptor
antagonism by SGAs (such as olanzapine) activate AMPK signaling in the
hypothalamic regions (MBH (Arc and VMH) and PVN)) (1)), possibly also the
brainstem DVC (2), leading to hyperphagia and weight gain. AMPK AMP-activated
protein kinase, Arc: arcuate nucleus, DVC: dorsal vagal complex; HA neuron:
histamine neuron, H1R: histamine H1 receptor, MBH: mediobasal hypothalamus,
PVN: paraventricular nucleus, TM: tuberomammillary nucleus, VMH: ventromedial
hypothalamus.
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B. Intracellular mechanisms for SGA-induced weight gain associated with H1
receptor antagonism
Although the intracellular downstream signaling pathway of H1 receptors in SGAinduced weight gain is not fully understood, studies have indicated that hypothalamic
AMPK signaling is significantly involved. Both in vitro and in vivo studies have
found that clozapine, olanzapine, and quetiapine, with high affinities for H1 receptors
and a high risk of inducing weight gain, significantly increased hypothalamic AMPK
(Kim et al., 2007, Martins et al., 2010, Sejima et al., 2011). Importantly, histamine
decreases pAMPK, which can be reversed by clozapine in mouse hypothalamic slices
(Kim et al., 2007). Clozapine-induced hypothalamic AMPK activation was also
abolished in H1 receptor knock-out mice (Kim et al., 2007). In contrast, SGAs with
lower obesogenic effect and lower H1 receptor affinities such as ziprasidone are less
effective at increasing hypothalamic AMPK activity (Kim et al., 2007). However, a
study in rats also reported that acute treatment of olanzapine (50 μg) or clozapine (25
mg/kg) did not significantly increase the hypothalamic AMPK phosphorylation and its
directly downstream ACC, although there was an increasing trend (Ferno et al., 2011).
Subchronic olanzapine treatment (6mg/kg/day, 5 days) reduced hypothalamic
pAMPK and pACC levels compared with vehicle (Ferno et al., 2011). It is suggested
that in this study, the lack of AMPK activation by the SGAs may also have been
caused by other factors, such as the drug doses used (high doses caused sedation),
time after the last drug injection (20 hours) and whether the rats were fasted or not.
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Taking the importance of H1 receptor in SGA-induced hyperphagia and the key role
of hypothalamic AMPK signaling in energy balance and body weight regulation
together, it is conceivable that by blocking H1 receptors in the hypothalamus, SGAs,
particularly clozapine and olanzapine, may activate the hypothalamic AMPK
signaling, leading to hyperphagia and weight gain (Figure 1.3). Moreover, as has been
discussed, H1 receptors in the Arc, VMH and PVN play a key role in feeding
regulation, in which AMPK signaling may act as a downstream pathway (Figure
1.2A). SGAs may activate the AMPK signaling in the Arc, VMH and PVN following
H1 receptor antagonism to up-regulate food intake and weight gain (Figure 1.2B). To
date, the role of hypothalamic H1 receptor-AMPK signaling in olanzapine-induced
weight gain has not been fully investigated. As has been discussed, within the
hypothalamus, the MBH (containing the Arc and VMH) is a major site that integrates
hormonal, nutritional and neurotransmitters information to regulate food intake and
body weight (Blouet et al., 2009, Maurin et al., 2014). Since Arc is too small, the
dissected Arc cannot rule out any adjacent brain areas, therefore, in the present study,
the MBH and PVN will be dissected to investigate the AMPK signaling, similar to
previous studies (Blouet et al., 2009, Lu et al., 2013, Maurin et al., 2014) .
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Figure 1.3 Potential role of hypothalamic H1 receptor-AMPK signaling in SGAinduced hyperphagia. Histamine, synthesised by the oxidative decarboxylation of
histidine by HDC (1), mediates feeding by acting at postsynaptic H1 receptors. The
synthesis and release of histamine is controlled by pre-synaptic H3 receptors. SGAs
such as olanzapine and clozapine competitively bind to H1 receptors in the
hypothalamus (2). H1 receptor antagonism by SGAs leads to AMPK activation (3).
Activated AMPK directly inhibits ACC activity, which results in decreased malonylCoA levels. The decrease in malonyl-CoA, which is an inhibitor of CPT1, disinhibits
CPT1 activity, and therefore increases food intake and causes weight gain. ACC:
Acetyl-CoA carboxylase, AMPK: AMP-activated protein kinase, CPT1: carnitine
palmitoyltransferase 1, FAS: fatty acid synthase, FI: food intake, HA neuron:
histamine neuron, HDC: histidine decarboxylase, H1R: histamine H1 receptor, H3R:
histamine H3 receptor, SGAs: second generation antipsychotics.
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1.2.4.2 Potential role of the H1 receptor and AMPK signaling in the brainstem
DVC in SGA-induced weight gain
In addition to the hypothalamus, H1 receptors and AMPK signaling in the DVC may
also play a role in SGA-induced weight gain. As has been discussed (in section 1.2.3),
the DVC is critical in food intake and body weight regulation (Hayes et al., 2009,
Hayes et al., 2011). Previous studies in rats found that the brainstem DVC is
significantly involved in mediating olanzapine-induced weight gain (Deng et al.,
2007, Weston-Green et al., 2008). Histamine neurons originating from the TM send
projections to the DVC (Watanabe et al., 1984, Bhuiyan et al., 2011). H1 receptors are
highly expressed in the DVC and predominantly located on neurons (Bhuiyan et al.,
2011). However the role of DVC H1 receptor in feeding regulation and its role in
SGA-induced weight gain has not been fully studied. Additionally, DVC AMPK has
been reported to respond to energy status and mediate food intake, energy expenditure
and body weight. AMPK activity in the NTS was increased in food deprived rats,
which was abolished by refeeding (Hayes et al., 2009). Both 4th icv and medial NTS
injection of an AMPK inhibitor, compound C, significantly reduced food intake,
increased heart rate and increased spontaneous activity in rats (Hayes et al., 2009).
Moreover, 4th icv injection of AMPK activator, 5-aminoimidazole-4-carboxamideriboside (AICAR), attenuated the inhibition of food intake induced by leptin (Hayes et
al., 2009). However, the role of DVC AMPK signaling in SGA-induced elevation of
food intake and weight gain is currently unknown. Taken together, it is important to
investigate the role of DVC H1 receptors and AMPK signaling in feeding regulation
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and their relationship with the hypothalamus to better understand the hypothalamusbrainstem circuits in feeding and body weight control, as well as their role in SGAinduced hyperphagia and obesity in particular with the use of olanzapine (Figure
1.2B).

1.2.5 A potential role of HDC and H3 receptor in SGA-induced weight gain
As has been discussed (section 1.2.3), HDC, a rate-limiting enzyme for histamine
production, plays an important role in mediating food intake and body weight. It has
been reported that antipsychotics such as olanzapine treatment modulate histamine
release in the prefrontal cortex, and that this effect may largely relate to antagonism of
the H1 receptor (Fell et al., 2012). In the hypothalamus, Murotani et al. (2011)
reported that an intraperitoneal injection of risperidone (which has a moderate H1
receptor affinity) but not haloperidol (which has a low affinity for H1 receptors)
increases the release of hypothalamic histamine in mice. However, how olanzapine
modulates hypothalamic histamine synthesis via HDC is not fully understood.

Moreover, as has been reviewed in Chapter 1 (section 1.2.5), the H3 receptor
antagonist may be effective to attenuate olanzapine-induced weight gain. An H1
receptor agonist/H3 receptor antagonist, betahistine, has been reported to reduce
olanzapine-induced weight gain in both human (Poyurovsky et al., 2012) and rat
model (Deng et al., 2012). These data suggest that although olanzapine has a low
affinity for the H3 receptors (Deng et al., 2010), H3 receptors may play an important
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role in olanzapine-induced weight gain. The presynaptic H3 receptor inhibits
histamine synthesis and release (Sakai et al., 1991). Centrally increasing histamine
level for 7 days by oral administration of L-histidine leads to a significant alteration of
the H3 receptor in the brain, although not in the hypothalamus in rats (Lozeva et al.,
2003). However, this absence of H3 receptor alteration in the hypothalamus may be
due to the short treatment period (Deng et al., 2010). These findings suggest that
olanzapine may also indirectly affect the central H3 receptors, and this effect may be
related to olanzapine-induced weight gain. Taken together, it is important to examine
the effect of olanzapine on HDC and H3 receptor expression in the hypothalamus to
determine the role of the central histaminergic system in SGA-induced weight gain.

1.2.6 Do the HDC, H3 receptor, H1 receptor and AMPK signaling play a
different role in the three stages of SGA-induced obesity?
In the clinic, previous research has indicated that antipsychotic-induced weight gain
(olanzapine and clozapine) occurs in different phases: In stage 1 (early acceleration,
the first 3 months), SGAs rapidly increase body weight; in stage 2 (middle new
equilibrium, 3-18 months), SGAs cause a steadier but lower rate of increasing body
weight; while in stage 3 (late heavy weight maintenance, > 18 months) the weight
gain reaches a plateau and increased body weight is maintained during SGA treatment
(Pai et al., 2012). For example, in a 2-year study in schizophrenia patients, olanzapine
(5-20mg/day) increased the mean weight gain by 9.2kg in the first 3 months, 15.5 kg
after 11 months and reached a plateau at 15.4 kg after 2 years (Zipursky et al., 2005).
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A recent clinical study (3 years) also reported that the maximum increase in body
weight induced by antipsychotics (olanzapine and risperidone) treatment occurred
within the first year (Perez-Iglesias et al., 2014). In rats, a similar effect of olanzapineinduced weight gain has also been reported, although the period of every stage is
shorter (Huang et al., 2006). These findings suggest that the mechanisms may vary
during the different stages of olanzapine-induced obesity development. Interestingly, a
number of studies found that olanzapine (1-8mg/kg/day) causes dramatic increase of
daily food intake particularly during short-term treatment (<2 weeks) in rats (Albaugh
et al., 2006, Huang et al., 2006, Stefanidis et al., 2008, van der Zwaal et al., 2012).
During long-term treatment, the olanzapine treatment group showed no significant
difference in food intake from week 3-5, but maintained a higher body weight
compared to the vehicle-treated control rats (Albaugh et al., 2006, Huang et al., 2006,
Stefanidis et al., 2008). In addition, pair-fed rats which were given the same amount
of food did not increase weight gain during short-term olanzapine treatment
(6mg/kg/day, oral, 5days) (Ferno et al., 2011). These findings support the hypothesis
that during short-term SGA treatment, the rapid increase in body weight may largely
be caused by hyperphagia. However, as treatment was prolonged, in which period
food intake is no different from the control; other factors may mainly contribute to
SGA-induced weight gain, for example the reduced energy expenditure. It has been
reported that patients treated with SGAs exert significantly decreased energy
expenditure (Sharpe et al., 2005, Skouroliakou et al., 2009, Cuerda et al., 2011, Pai et
al., 2012). Olanzapine, clozapine and quetiapine have been found to decrease energy
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expenditure in animal models of rats (Blessing et al., 2006, Monda et al., 2006,
Stefanidis et al., 2008). Taken together, the evidence suggests that the central HDC,
H3 receptor, H1 receptor and H1 receptor-associated AMPK signaling pathway may
play a different role in different stages of SGA-induced obesity.

1.2.7 Conclusions
SGAs, in particular clozapine and olanzapine, drugs commonly used in the clinic to
treat schizophrenia, significantly cause weight gain/obesity. However the mechanisms
are not fully understood. Accumulated data suggest that central H1 receptor
antagonism plays a key role in SGA-induced weight gain development (MatsuiSakata et al., 2005, Kim et al., 2007, Han et al., 2008, Deng et al., 2012). The H1
receptor occupancy strongly predicts weight gain liability of an SGA (Kroeze et al.,
2003, Matsui-Sakata et al., 2005), while activation of histamine H1 receptors by
betahistine, for example, effectively blocks SGA-induced obesity (Deng et al., 2012,
Poyurovsky et al., 2012). The hypothalamic AMPK signaling is affected by the
antipsychotic medication possibly via the H1 receptor contributing to body weight
gain, although other systems should not be ignored in this context (eg: serotonin 2C
receptor). Additionally, previous research also indicated a potential role of HDC and
H3 receptors in SGA-induced weight gain. Moreover, recent research has indicated
that the development of SGA-induced obesity is time-dependent; increased food
intake may only be responsible for rapid increase in weight during short-term
treatment, while other mechanisms such as energy expenditure may play a role during
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long-term treatment (Pai et al., 2012). These findings suggest that the central
histaminergic system and its associated AMPK signaling may play a time-dependent
role in the development of olanzapine-induced obesity. An improved understanding of
the role of histamine neurotransmission, in particular the H1 receptor and its
associated signaling pathways, in SGA-induced weight gain could help in designing a
better treatment strategy for preventing and treating SGA-induced weight gain.

The present thesis investigated the role of the brain histaminergic system in the early
(8 days), middle (16 days) and late (36 days) stage of olanzapine-induced weight gain
in female rats. The choice of examining 8, 16 and 36 days after olanzapine treatment
was based on the previous work of our research group (Huang et al., 2006, Han et al.,
2008). In this work, we showed that the pattern of weight gain in our rat model during
the course of short, medium and long term olanzapine treatment is similar to clinical
data (Allison and Casey, 2001, Pai et al., 2012, Deng, 2013). The full course of
obesity development is about 36 days in rats and one year in humans (Zipursky et al.,
2005). In terms of gender differences, growing evidence from both clinical studies
(Weston-Green et al., 2010) and animal models (Albaugh et al., 2006, Sejima et al.,
2011, Davey et al., 2012) has suggested that females are more sensitive than males to
olanzapine-induced weight gain side effects.
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1.3 Aims of the study

1.3.1 General aim
This project aims to investigate the role of the histaminergic system and its associated
AMPK signaling pathway in the hypothalamus and brainstem DVC in olanzapineinduced food intake and obesity.

1.3.2 Specific aims
The specific aims of the present research were:
1. Examine the effect of olanzapine on the expression of hypothalamic HDC, H1
receptor and H3 receptor at the early, middle and late stages (olanzapine
treatment for 8, 16 and 36 days) of olanzapine-induced obesity in female rats
2. Examine the effect of olanzapine on the hypothalamic H1 receptor-AMPK
signaling pathway at the early, middle and late stages of olanzapine-induced
obesity, and whether central injection of a selective H1 receptor agonist is able
to block these effects
3. Examine the effect of olanzapine on the H1 receptor and AMPK signaling in
the brainstem DVC at the early, middle and late stages of olanzapine-induced
weight gain, and whether central injection of a selective H1 receptor agonist is
able to block these effects
4. Examine the acute intramuscular injection of olanzapine on weight gain and
the H1 receptor-AMPK signaling in the specific hypothalamic regions (MBH
and PVN) and brainstem DVC (olanzapine treatment: 1 injection and 9
injections (tid, 3 days in total))
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1.3.3 Hypothesis
The brain histaminergic system and its associated AMPK signaling pathway may have
a critical role in different stages of olanzapine-induced elevated food intake and
weight gain.
1. The HDC, H1 receptor and H3 receptor will act differently in the different
stages of olanzapine-induced obesity. There will be a significant relationship
between the alterations of HDC, H1 receptor and H3 receptor with food intake
and weight gain
2. In

a

time-dependent

manner,

olanzapine

will

significantly

activate

hypothalamic AMPK signaling pathway via blocking the H1 receptors
compared with the vehicle-treated group. The activation of AMPK signaling
pathway induced by olanzapine will correlate to olanzapine-induced elevation
of food intake and weight gain. Co-administration of the H1 receptor agonist
(2-(3- trifluoromethylphenyl) histamine (FMPH) and olanzapine will dose- and
time-dependently block olanzapine-induced food intake. FMPH will attenuate
olanzapine-induced AMPK activation in the hypothalamus. These changes will
correlate to changes in food intake.
3. Olanzapine will significantly activate DVC AMPK signaling pathway via
blocking the H1 receptors in a time-dependent manner, compared with the
vehicle-treated group. There changes induced by olanzapine will correlate to
olanzapine-induced elevation of food intake and weight gain. Co29

administration of the H1 receptor agonist, FMPH, and olanzapine will doseand time-dependently block olanzapine-induced AMPK activation in the DVC.
These changes will correlate to changes in food intake.
4. Acute treatment of olanzapine (1 injection and 9 injections) will significantly
activate the AMPK signaling in the hypothalamic specific regions (MBH and
PVN) and brainstem DVC. These changes will cause hyperphagia, and thus
lead to rapid weight gain.

1.3.4 Significance
By understanding the role of the histaminergic system and its associated AMPK
signaling pathway in olanzapine-induced food intake and obesity may assist better
understanding the mechanism of hypothalamic regulation of food intake as well as the
SGA-induced hyperphagia and obesity. In addition, it can provide a straightforward
approach to developing better antipsychotic drugs with lower risk of inducing obesity
compared to olanzapine. Furthermore, it may help to reduce the drug non-compliance,
and find new therapeutic targets for treating obesity both in the general population
and schizophrenia patients.
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CHAPTER 2

TIME-DEPENDENT EFFECTS OF OLANZAPINE TREATMENT ON THE
EXPRESSION OF HDC, H1 AND H3 RECEPTOR IN THE RAT BRAIN: THE
ROLES IN OLANZAPINE-INDUCED WEIGHT GAIN

2.1 Introduction
The histamine H1 receptor has been identified as an important contributor to
antipsychotic-induced weight gain, particularly olanzapine and clozapine (Kroeze et
al., 2003, Matsui-Sakata et al., 2005). Studies have reported that olanzapine and
clozapine altered H1 receptor expression in the rat hypothalamus (Han et al., 2008,
Humbert-Claude et al., 2012). However, how olanzapine modulates histaminergic
neurotransmission in the hypothalamus, and its potential associations with olanzapineinduced food intake and weight gain, is currently poorly understood.

Histaminergic neurons, located at the TM in the posterior hypothalamus, project to
many brain areas including the hypothalamus and DVC (Haas et al., 2008). Histamine
is synthesized by the oxidative decarboxylation of histidine by the enzyme HDC
(Haas et al., 2008). Histamine is then stored in axon varicosities or released into the
synaptic cleft (Haas et al., 2008). Both the synthesis and release of histamine are
controlled by the presynaptic H3 receptors (Torrent et al., 2005). Hypothalamic
histamine regulates food intake and energy expenditure by activating the postsynaptic
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H1 receptors in the hypothalamic PVN, VMH and Arc (Sakata et al., 1988, Ookuma
et al., 1993, Umehara et al., 2010).

HDC exists in most mammalian tissues and is highly expressed in the TMN where
neuronal histamine is produced (Krusong et al., 2011). Inhibition of HDC blocks the
synthesis of histamine, and attenuates the suppressive effect of histidine on food
intake (Yoshimatsu et al., 2002). HDC knock-out mice have an increased body weight
and epididymal adipose tissue (Yoshimatsu et al., 2002). Olanzapine treatment
modulates histamine tone in the prefrontal cortex, and this effect may largely relate to
antagonism of the H1 receptor (Fell et al., 2012). However, the effect of olanzapine
on hypothalamic histamine synthesis has not been reported.

The H3 receptor is highly expressed in the hypothalamus (Pillot et al., 2002)
inhibiting histamine synthesis and release. The H3 receptor antagonists, for example
NNC 38-1049, have been reported to decrease food intake (Malmlof et al., 2005).
Previous studies show that the H3 receptor mediates food intake partly by regulating
the inhibition of histamine synthesis and release (Malmlof et al., 2005, Ishizuka et al.,
2008). Since olanzapine treatment may modulate the histaminergic system in the
hypothalamus, it is possible that olanzapine may also affect H3 receptor expression,
although olanzapine has been proven to have a low affinity for the H3 receptors.
Further examination of the H3 receptor alteration in olanzapine-induced weight gain
is warranted to better understand how the histaminergic system is modulated by
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olanzapine, and what its role is in olanzapine-induced weight gain.

Moreover, clinical evidence (Allison and Casey, 2001, Pai et al., 2012) and animal
studies (Huang et al., 2006) indicate that antipsychotic-induced obesity occurs in three
stages: rapid increases of body weight in the early acceleration stage; a reduced rate of
weight gain in the middle new equilibrium stage; and finally, body weight plateaus
and is maintained with continuing olanzapine treatment. Therefore, it is suggested that
olanzapine may time-dependently modulate the histamine neurotransmission, which
may play a role in olanzapine-induced weight gain. This study therefore has
investigated the effect of olanzapine on the key components of histaminergic system,
HDC, H1 receptor and H3 receptors, in different stages of olanzapine-induced weight
gain.

2.2 Materials and methods
2.2.1 Animals and housing
Female Sprague-Dawley (SD) rats (weight 200-225g) were obtained from the Animal
Resources Centre (Perth, WA, Australia). The rats were housed under environmentally
controlled conditions (22°C on a 12h light-dark cycle (lights on 0700 h)). Rats were
allowed ad libitum access to food and water throughout the studies. All animal
experiments were approved by the Animal Ethics Committee, University of
Wollongong, and complied with the Australian Code of Practice for the Care and Use
of Animals for Scientific Purposes (2004). Olanzapine (Zyprexa) was obtained from
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Eli Lilly, Indianapolis, IN, USA.

2.2.2 Olanzapine treatment
A rat model that mimics the clinical olanzapine-induced weight gain has been
established in our laboratory (Zhang et al., 2014a). In order to examine the effect of
olanzapine on the hypothalamic HDC, H1 receptor and H3 receptor expression in
different stages of olanzapine-induced weight gain, rats were treated with olanzapine
for 8 days, 16 days and 36 days to represent the three stages of olanzapine-induced
weight gain (Zhang et al., 2014a). SD rats (12 weeks old) were randomly divided into
three groups and treated with olanzapine (Eli Lilly, Indianapolis, IN, USA) or vehicle
for 8, 16 and 36 days. Olanzapine (1 mg/kg) or vehicle was administered orally three
times daily (equivalent to 3 mg/kg/day) at eight-hourly intervals at 0700 h, 1500 h and
2300 h (n = 12/group). The rats were fed sweet cookie dough (62% carbohydrate,
22% protein, 6% fibre, 10% vitamins and minerals) mixed with either olanzapine or
placebo (Zhang et al., 2014a). Food intake and body weight were recorded every 2
days. In this study, female rats were chosen since previous studies reported that
olanzapine treatment increased food intake, weight gain and adiposity in female rats
(Huang et al., 2006, Weston-Green et al., 2011), which is consistent with the clinical
findings of female gender as a risk factor for antipsychotic-induced weight
gain/obesity (Roumestan et al., 2008). The dosage of olanzapine was chosen based on
our previous studies (Weston-Green et al., 2011). It was calculated towards the
clinically relevant dosage of 10 mg/day (based on body surface area of different
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species) (Reagan-Shaw et al., 2008), and mimicked the olanzapine-induced obesity in
the clinical setting.

2.2.3 Histologic procedures
All rats were sacrificed using carbon dioxide (CO2) (Han et al., 2008). The periovary,
perirenal, inguinal, omental fat mass were weighed after the rats were sacrificed. The
brains from a half of the rats from each treatment group were used for real-time PCR
studies (n = 6) and the other half for receptor autoradiography (n = 6). For the realtime PCR, the rats were sacrificed 2 hours after the last drug treatment to investigate
the immediate effect of olanzapine on the gene expression (Huang et al., 2006), and
the hypothalami were quickly dissected on ice, frozen in liquid nitrogen and then
stored at -80 °C. For the receptor binding experiments, rats were sacrificed 48 h after
the last drug treatment (Han et al., 2008, Weston-Green et al., 2008). The brain tissues
were immediately removed and stored at -80 °C until sectioning. Brains were
cryostatically cut to 14 µm coronal sections at -18 °C and thaw-mounted onto
PolysineTM Microscopeslides (Menzel GmbH & Co. KG, Braunschweig, Germany)
and stored at -20 °C. The brain regions were chosen based on the standard rat brain
atlas (Paxinos and Watson, 2007).
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2.2.4 Receptor autoradiography and quantification
2.2.4.1 Histamine H1 receptor binding and quantification
Previous studies in humans and rodents have demonstrated that the H1 receptors were
rich in the cortical regions such as the prefrontal, cingulate, and primary motor cortex
(M1), middle brain areas such as the ventral tegmental area and hypothalamus, and
the limbic regions such as the hippocampus (HIP), caudate putamen (CPu) and medial
posterodorsal amygdala (MeP) (Iwabuchi et al., 2005, Jin and Panula, 2005, Hu et al.,
2010). In the hindbrain, H1 receptors are abundant in the brainstem DVC (Poole et al.,
2008, Bhuiyan et al., 2011). The present study examined the effect of 8, 16 and 36day olanzapine treatment on the H1 receptor binding density in the prefrontal cortex
(PFC), M1, cingulate cortex (Cg), CPu, accumbens nucleus, core (AcbC), Arc, PVN,
VMH, DMH, LHA, HIP, MeP and brainstem DVC.

The H1 receptor binding autoradiography was performed using the procedures
described previously (Hu et al., 2010). Briefly, slide sections were left to thaw and dry
at room temperature before the binding procedures were carried out. Then, sections
were incubated with 5 nM [3H]pyrilamine (specific activity 27.0 Ci/mmol, Amersham
Biosciences UK Limited) in 50 mM sodium potassium phosphate buffer (pH 7.4) for
1 hour (Han et al., 2008, Hu et al., 2010). The non-specific binding was detected by
adding 10 µM triprolidine (Sigma) using the same buffer. After incubation, the
sections were washed in ice-cold buffer (4 × 2 min), dipped in ice-cold distilled water
and dried under a stream of cold air to remove excess buffer salts. The non-specific
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binding was detected by adding 10 µM triprolidine (Sigma). All of the slides were
exposed to Amersham high performance autoradiography film (GE healthcare,
pallards Wood, UK) for 3 months. The films were developed using standard
procedures. Sampling in different brain regions was carried out based on (Paxinos and
Watson, 2007). The H1 receptor binding density in various brain areas was performed
by measuring the average density of each brain region in three adjacent brain sections
in both brain hemispheres (Han et al., 2008, Hu et al., 2010). Quantification of the
autoradiographic images was performed using a computer-assisted image analysis
system, Multi-Analyst (Bio-Rad, Hercules, California, USA), by measuring different
brain regions in grey-scale pixel values (Han et al., 2008). Linearization was done
based on standard [3H] microscales from Amersham, which contain a series of known
amount of radioligands (Zavitsanou et al., 2002). The relative optical density was
converted to nCi[3H] ligand per mg tissue equivalent based on the [3H] microscales
standard curve (Zavitsanou et al., 2002). The specific binding values were obtained by
subtracting non-specific binding values from the total binding values. Brain regions
were identified based on the rat brain atlas (Paxinos and Watson, 2007).

2.2.4.2 Histamine H3 receptor binding and quantification
Previous studies have shown that H3 receptor are distributed in the cortical areas
(PFC, M1 and Cg), forebrain areas (nucleus accumbens), middle brain areas
(hypothalamic VMH and PVN), and limbic regions (CPu and MeP) (Pollard et al.,
1993, Pillot et al., 2002). In the DVC, H3 receptor density was very low (Pillot et al.,
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2002). The present study examined the effects of olanzapine treatment on the H3
receptor binding density in the hypothalamic Arc, PVN, VMH, DMH, and LHA, as
well as PFC, Cg, M1, CPu, AcbC and MeP.

The procedure for the H3 receptor autoradiography was based on standard procedures
from (Anichtchik et al., 2000, Le et al., 2009) using 4 nM [3H]NAMH (specific
activity 84.4 Ci/mmol, PerkinElmer (Waltham, MA)) (Anichtchik et al., 2000).
Briefly, sections were incubated in the binding buffer containing 150 mM Na2/K
phosphate buffer (PH7.4), 2 mM MgCl2, 100 µM dithiothreitol and 4 nM [3H]NAMH
for 45 min at room temperature. Non-specific binding was identified using 5 µM
clobenpropit in incubation buffer. After incubation, the sections were washed with
ice-cold buffer (3 × 2 min) and dipped in ice-cold distilled water. The sections were
rapidly dried using a stream of cold air. All of the slides were exposed to Amersham
high performance autoradiography film (GE healthcare, pallards Wood, UK) for 3
months. The quantification of the H3 receptor was performed using the same
procedure as the H1 receptor.

2.2.5 Real-time quantitative PCR
Dissected hypothalamus was homogenized and RNA was isolated using PurlinkTM
RNA Mini Kit (Life Technologies, NSW, Australia) following the manufacturer‘s
instructions. RNA was converted to cDNA using Superscript® VILOTM cDNA
Synthesis Kit (Life Technologies). RT-PCR was performed using LightCycler® 480
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Real-Time PCR instrument (Roche Applied Science, NSW, Australia) with the
TaqMan® Gene Expression Assays (Life Technologies): HDC (assay no.
Rn00566665_m1) and H3 receptors (Rn00585276_m1). β-actin (assay no.
Rn00667869_m1) was used as an endogenous control. The amplification was run with
40 cycles of denaturation at 95°C followed by annealing and extending at 60°C. The
results were calculated using the 2-∆∆CT method (Schmittgen and Livak, 2008).
Briefly, when comparing the gene expression in two different samples (olanzapine vs.
vehicle), the fold change of gene expression = 2-∆∆CT = [(CT gene of interest - CT
internal control) olanzapine-(CT gene of interest - CT internal control) vehicle)] (CT:
threshold cycle) (Schmittgen and Livak, 2008).

2.2.6 Statistics
The statistics were performed using the SPSS 19.0 program (Chicago, IL, USA).
Two-way analysis of variance (ANOVA) (olanzapine × time as repeated measure)
followed by an independent unpaired student‘s t-test (two-tailed) were used to analyse
the statistical differences in energy intake and weight gain between olanzapine and the
control groups. Three-way ANOVAs (olanzapine × time × brain region) were used to
analyse H1 and H3 receptor binding density in relative rat brain regions. The
independent student‘s t-test was followed for comparison of differences between
groups. The differences in fat mass (periovary, perirenal, inguinal, omental and total
fat mass), liver, HDC and H3 receptor mRNA expression were analysed using an
independent unpaired student t-test (two-tailed). Correlations were identified using
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Pearson‘s correlations. All data were presented as mean ± SEM. Statistical
significance was defined as p < 0.05.

2.3 Results

2.3.1 Food intake, weight gain, water intake and fat mass following 8, 16 and 36
days olanzapine treatment
When food intake was measured every 48 h, olanzapine treatment only induced a
significantly elevation of food intake during the first 12 days (Figure 2.1A; two-way
analysis of variance (olanzapine × time as repeated measure) followed by an
independent student‘s t test for each time point, all p < 0.05 vs. control, n = 12/group)
but not during day 14-36 (all p > 0.05). Rats treated with olanzapine had a higher
body weight throughout the whole treatment period (all p < 0.05 vs. control), during
which olanzapine rapidly increased body weight in the first 12 days (early stage),
slowed down from day 13 to 28 (middle stage), and then reached a plateau from day
29 to 36 (late stage) (Figure 2.1B). Pearson's correlations revealed that the cumulative
food intake was significantly correlated with body weight gain in the early stage of
olanzapine-induced obesity but not in the middle and late stages (r = 0.656, p = 0.001;
r = 0.356, p = 0.095; r = 0.261, p = 0.240, respectively). These data suggest that
hyperphagia may only contribute to olanzapine-induced weight gain during short-term
treatment. Cumulative food intake, weight gain and feeding efficiency were increased
after 8-, 16- and 36-day olanzapine treatment (all p < 0.05 vs. control, Table 2.1). The
water intake was not changed by olanzapine treatment during all the treatment period
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(Figure 2.1C). Olanzapine treatment also had a significant effect on visceral adiposity
including the subcutaneous periovary, perirenal, inguinal but not omental fat mass
during all three treatment cohorts (Table 2.1). The total fat mass (periovary + perirenal
+ inguinal + omental) were significantly increased by olanzapine in all the three
experiment periods (all p ≤ 0.01 vs. control, Table 2.1).

2.3.2 The effect of olanzapine on the gene expression of the hypothalamic HDC
and H3 receptor
The 8-day olanzapine treatment significantly increased the mRNA expression of HDC
(t = 2.797, df = 6, p = 0.031 vs. control, Figure 2.2 A) in the hypothalamus. The
hypothalamus HDC expression was positively correlated with the last 48 h food
intake (r = 0.943, p = 0.000), weight gain (r = 0.849, p = 0.008) and feeding
efficiency (the ratio of cumulative weight gain / total food intake) (r = 0.792, p =
0.019). These findings suggest that olanzapine-induced time-dependent changes in the
mRNA expression of HDC may be related to olanzapine-induced weight gain.
However, both 16- and 36-day olanzapine treatments did not significantly alter the
mRNA expression of HDC in the hypothalamus (all p > 0.05 vs. control, Figure 2.2 B
and C). The mRNA expression of hypothalamic H3 receptor was not significantly
altered by olanzapine during any of the three treatment periods (all p > 0.05 vs.
control, Figure 2.2 D-F).
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Figure 2.1. Effects of olanzapine (1 mg/kg, tid) on 48 h food intake (A), weight gain
(B) and 48 h water intake (C). Rats were trained to eat cookie dough containing
olanzapine or vehicle as indicated for 36 days (see ‗Materials and Methods‘) (n =
12/group). All data are presented as mean ± SEM. Statistical significance was defined
as p < 0.05 (* p < 0.05, ** p < 0.01 vs. control).
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Figure 2.2 Effects of olanzapine (1 mg/kg, tid) treatment on the mRNA expression of
HDC (A, B, C) and the H3 receptor (D, E, F) in the rat hypothalamus after 8-, 16- and
36-day treatments. All data are presented as mean ± SEM. Statistical significance was
defined as p < 0.05 (* p < 0.05 vs. control)
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Table 2.1 Body weight gain and fat mass of rats treated with olanzapine or vehicle for 8, 16 and 36 days.

Con
CWG (g)
CFI (g)
FE
Fat mass
(g)
Periovary
Perirenal
Inguinal
Omental
Fat mass
Other (g)
Liver

8 days
OLZ

p

Con

16 days
OLZ

36 days
OLZ

p

Con

2.6 ± 0.7
158.1 ± 5.2
0.03 ± 0.01

9.6 ± 0.6
185.1 ± 4.2
0.12 ± 0.01

0.000
0.001
0.000

22.2 ± 1.1
402.0 ± 12.8
0.05 ± 0.00

36.3 ± 3.0
466.4 ± 18.8
0.09 ± 0.01

0.000
0.009
0.000

40.8 ± 3.5
739.5 ± 34.4
0.05 ± 0.00

51.9 ± 2.7
838.8 ± 20.2
0.07 ± 0.00

0.022
0.005
0.039

p

2.2 ± 0.2
1.8 ± 0.1
1.5 ± 0.1
0.4 ± 0.1
6.1 ± 0.5

3.1 ± 0.2
2.7 ± 0.2
1.8 ± 0.1
0.5 ± 0.1
8.2 ± 0.3

0.000
0.004
0.004
0.435
0.002

3.7 ± 0.4
3.3 ± 0.4
1.9 ± 0.2
0.7 ± 0.1
9.6 ± 0.9

5.7 ± 0.5
4.5 ± 0.4
2.7 ± 0.3
0.8 ± 0.1
13.7 ± 1.1

0.004
0.032
0.017
0.502
0.010

4.4 ± 0.5
3.4 ± 0.4
1.9 ± 0.1
0.7 ± 0.1
10.1 ± 0.9

5.9 ± 0.3
4.4 ± 0.2
2.5 ± 0.1
0.7 ± 0.1
11.0 ± 0.2

0.011
0.019
0.012
0.846
0.004

9.6 ± 0.3

11.3 ± 0.4

0.003

10.1 ± 0.4

11.4 ± 0.3

0.019

10.6 ± 0.4

11.0 ± 0.2

0.411

Abbreviations: Con: control; CFI: cumulative food intake; CWG, cumulative weight gain; FE: feeding efficiency; OLZ: olanzapine. Statistical
significance was defined as p < 0.05. Significant changes are indicated in bold.
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2.3.3 The effects of olanzapine on H1 receptor binding in the brain
The effects of olanzapine on the H1 receptor binding density in the brain have been
examined using receptor autoradiography following the 8-, 16- and 36-day
olanzapine treatments. Three-way ANOVA showed that there were significant main
effects of brain region (F[11,322] = 67.7, p = 0.000) and treatment period (F[2,322] =
200.5, p = 0.000), as well as significant interactions between brain region and drug
(F[11,322] = 7.7, p = 0.000), and interaction between brain region and treatment period
(F[22,,322] = 17.2, p = 0.000). However, there was no significant interaction between
all the three factors (p > 0.05). In the hypothalamus, the effects of olanzapine on H1
receptor binding density in the Arc, PVN, VMH LHA and DMH have been
examined (Figure 2.3A-B‘‘). Compared with control group, 8 day olanzapine
treatment (early stage) increased the H1 receptor binding density in the Arc (by 25%,
t = 3.109, df = 8, p = 0.014) and VMH (by 32%, t = 2.723, df = 8, p = 0.026) but not
in the PVN, DMH, LHA (Figure 2.4A, 2.5A-D). Pearson‘s correlation revealed that
the Arc H1 receptor binding density was significantly correlated with feeding
efficiency and cumulative weight gain (Table 2.2). The H1 receptor binding density
in the brainstem DVC (Figure 2.4B, 2.6A-D) and other brain regions examined
(PFC, CPu and M1 etc.) were not significantly altered by olanzapine (Table 2.3).
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Figure 2.3 Representative autoradiograms showing H1 receptor binding in the rat
hypothalamus. A-B, the schematic diagram was adopted from a rat brain atlas
(Paxinos and Watson, 2007). A’–B’’, Examples of photographs show the [3H]
pyrilamine binding to H1 receptors and non-specific binding in the hypothalamus.
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic
nucleus; LHA, lateral hypothalamus; PVN, paraventricular hypothalamic nucleus;
VMH, ventromedial hypothalamic nucleus.

After the 16-day treatment, the H1 receptor binding density in the hypothalamic Arc
and VMH were significantly elevated (Arc: by 25%, t = 2.799, df = 8, p = 0.046;
VMH: by 31%, t = 3.003, df = 9, p = 0.015, Figure 2.4C, 2.5E and F). Both the Arc
and VMH H1 receptor binding density significantly positively correlated with
feeding efficiency and weight gain (Table 2.2). Olanzapine also induced an increased
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DVC H1 receptor binding (DVC: by 20%, t = 2.611, df = 9, p = 0.030, Figures 2.4D,
2.6E and F), in which the H1 receptor expression was positively correlated with
weight gain (r = 0.668, p = 0.025) and feeding efficiency (r = 0.667, p = 0.025).

After the 36-day treatment, olanzapine induced an increased H1 receptor binding in
the hypothalamic Arc (by 32%, t = 2.694, df = 9, p = 0.025) and VMH (by 45%, t
=5.570, df = 10, p = 0.000) (Figure 2.4E, 2.5G and H) and the brainstem DVC (by
22%, t = 5.085, df = 7, p = 0.001) (Figure 2.4F, 2.6G and H). The H1 receptor
binding density in the Arc and VMH were positively correlated with weight gain
(Table 2.2), and the DVC H1 receptor binding tended to be correlated with weight
gain (r = 0.714, p = 0.071). Moreover, a significant increase was found in the H1
receptor binding density in the MeP after the 36-day olanzapine treatment (29%, t =
2.994, df = 8, p = 0.029, Table 2.3), in which H1 receptor expression tended to be
correlated with cumulative weight gain (r = 0.633, p = 0.067) and cumulative food
intake (r = 0.612, p = 0.060).
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Figure 2.4 The effect of olanzapine on the H1 receptor expression (nCi/mg tissue) in
the hypothalamic Arc, PVN, VMH, DMH, and LHA, and brainstem DVC after 8 (A,
B), 16 (C, D), and 36-day (E, F) treatments. All data are presented as mean ± SEM.
Statistical significance was defined as p < 0.05 (*p < 0.05, **p < 0.01 vs. control).
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic
nucleus; DVC, dorsal vagal complex; LHA, lateral hypothalamic area; PVN,
paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus.
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Figure 2.5 Map (A) and example (B) of H1 receptor binding in the hypothalamus,
and examples of H1 receptor binding in the hypothalamus after 8 (C, D), 16 (E, F),
and 36-day (G, H) olanzapine or vehicle treatments. Arc: arcuate nucleus, VMH:
ventromedial hypothalamus.
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Figure 2.6 Map (A) and example (B) of H1 receptor binding in the DVC, and
examples of H1 receptor binding in the brainstem DVC for 8 (C, D), 16 (E, F), and
36-day (G, H) olanzapine or vehicle treatments. DVC: dorsal vagal complex
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Table 2.2 Correlations within the hypothalamic H1 receptor binding density, feeding
efficiency and cumulative weight gain during different terms of olanzapine treatment
(8, 16 and 36 days).

8 days

16 days
Arc

Arc

VMH

H1R

r (P-value)

r (P-value)

FE
WG

0.742(0.022*) 0.520(0.152)

0.682(0.030*) 0.812(0.002**) 0.721 (0.028*)

0.609 (0.061)

0.718(0.029*) 0.524(0.147)

0.651(0.041*) 0.769(0.006**) 0.760 (0.017*)

0.633(0.049*)

r (P-value)

VMH

36 days

r (P-value)

Arc
r (P-value)

VMH
r (P-value)

Abbreviations: H1R: H1 receptor; FE: feeding efficiency; WG: weight gain; Arc:
arcuate nucleus; VMH: ventromedial hypothalamus. Statistical significance was
defined as p < 0.05 (*, p < 0.05, **, p < 0.01). Significant correlations are indicated
in bold.
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Table 2.3 Specific [3H] pyrilamine binding (nCi/mg tissue; mean ± SEM) to H1 receptors in different brain regions following different terms (8,
16, and 36 days) of olanzapine or vehicle treatment.

Brain region
AcbC
Arc
Cg
CPu
DMH
DVC
HIP
LHA
M1
PFC
PVN
VMH

8 days (n = 6)
Con
OLZ
1.13 ± 0.05
1.67 ± 0.08
1.78 ± 0.14
1.33 ± 0.14
1.15 ± 0.11
1.07 ± 0.14
0.52 ± 0.10
0.70 ± 0.12
1.79 ± 0.15
1.72 ± 0.17
1.24 ± 0.19
1.21 ± 0.12

1.07 ± 0.19
2.09 ± 0.11
1.49 ± 0.19
1.28 ± 0.11
1.05 ± 0.14
1.16 ± 0.14
0.55 ± 0.08
0.59 ± 0.10
1.48 ± 0.19
1.37 ± 0.17
1.71 ± 0.12
1.60 ± 0.08

P
value
0.767
0.014
0.241
0.844
0.584
0.710
0.602
0.448
0.225
0.184
0.067
0.026

16 days (n = 6)
Con
OLZ
1.63 ± 0.29
3.38 ± 0.05
2.16 ± 0.23
1.54 ± 0.22
2.53 ± 0.12
1.93 ± 0.08
1.56 ± 0.14
1.62 ± 0.10
2.27 ± 0.25
2.51 ± 0.10
1.96 ± 0.20
2.78 ± 0.14

1.06 ± 0.14
4.25 ± 0.30
1.62 ± 0.12
1.39 ± 0.31
2.25 ± 0.23
2.32 ± 0.13
1.77 ± 0.17
1.56 ± 0.12
1.69 ± 0.14
2.04 ± 0.28
2.34 ± 0.22
3.64 ± 0.27

P
value
0.119
0.046
0.067
0.701
0.983
0.030
0.354
0.728
0.073
0.190
0.227
0.015

36 days (n = 6)
Con
OLZ
0.70 ± 0.10
2.49 ± 0.27
0.88 ± 0.12
0.55 ± 0.10
2.46 ± 0.27
1.69 ± 0.08
0.91 ± 0.05
1.72 ± 0.06
0.93 ± 0.14
0.92 ± 0.14
1.73 ± 0.20
2.03 ± 0.16

0.55 ± 0.08
3.31 ± 0.08
0.81 ± 0.06
0.47 ± 0.07
2.42 ± 0.12
2.13 ± 0.04
1.17 ± 0.13
1.76 ± 0.12
0.90 ± 0.06
0.84 ± 0.11
1.84 ± 0.27
2.94 ± 0.05

P
value
0.276
0.025
0.633
0.537
0.903
0.002
0.118
0.632
0.895
0.659
0.761
0.000

Abbreviations: AcbC, accumbens nucleus, core; Arc, arcuate hypothalamic nucleus; Cg, cingulate cortex; CPu, caudate putamen; DMH,
dorsomedial hypothalamic nucleus; DVC, dorsal vagal complex; HIP, hippocampus; LHA, lateral hypothalamic area; M1, primary motor
cortex; PFC, prefrontal cortex; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus. Con: Control; OLZ:
olanzapine. Statistical significance was defined as p < 0.05. Significant changes in H1 receptor binding density are indicated in bold.
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2.3.4 The effects of olanzapine on H3 receptor binding in the brain
Whether olanzapine treatment affects the H3 receptor binding density in the brain
particularly the hypothalamus（Figure 2.7A-B‘‘）has also been investigated. Threeway ANOVA showed that there were significant effects of brain region factor
(F[10,274] = 8.5, p = 0.000) and treatment period factor (F[2,274] = 99.1, p = 0.000), and
significant interactions between brain region and treatment period (F[20,,274] = 5.7, p =
0.000), drug treatment and period (F[2,,274] = 3.2, p = 0.042), however no interactions
of all the three factors (p > 0.05). Compared with control group, the 8-day
olanzapine treatment did not significantly affect the H3 receptor binding in the
hypothalamic Arc, PVN, VMH, DMH, LHA (Figure 2.8A) or the other brain regions
examined (Table 2.4). The 16-day olanzapine treatment non-significantly decreased
the H3 receptor binding in the hypothalamic Arc (by 32%, t = 2.027, df = 8, p =
0.077, Figure 2.8B). The 36-day olanzapine treatment non-significantly decreased
the H3 receptor binding in the Arc in the olanzapine group compared with the
control group (by 37%, t = 2.146, df = 8, p = 0.064, Figure 2.8C), and the H3
receptor binding was negatively correlated with weight gain (r = -0.767, p = 0.019)
(images for comparing the H3 receptor binding between the olanzapine and control
groups are not shown because no significant differences were found between these
groups).
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Figure 2.7 Representative autoradiograms showing H3 receptor binding in the rat
hypothalamus. A-B, the schematic diagram was adopted from a rat brain atlas
(Paxinos and Watson, 2007). A’–B’’, Examples of photographs show the [3H]
NAMH binding to H3 receptors and non-specific binding in the hypothalamus.
Abbreviations: Arc, arcuate hypothalamic nucleus; DMH, dorsomedial hypothalamic
nucleus; LH, lateral hypothalamus; PVN, paraventricular hypothalamic nucleus;
VMH, ventromedial hypothalamic nucleus.
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Figure 2.8 The effect of olanzapine on the H3 receptor expression (nCi/mg tissue) in
the hypothalamic Arc, PVN, VMH, DMH, and LHA after 8 (A), 16 (B), and 36-day
(C) treatments. All data are presented as mean ± SEM. Statistical significance was
defined as p < 0.05. Abbreviations: Arc, arcuate hypothalamic nucleus; DMH,
dorsomedial hypothalamic nucleus; LHA, lateral hypothalamic area; PVN,
paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus.
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Table 2.4 Specific [3H]NAMH binding (nCi/mg tissue; mean ± SEM) to H3 receptors in different brain regions following different terms (8, 16,
and 36 days) of olanzapine or vehicle treatment.

Brain
region
AcbC
Arc
Cg
CPu
DMH
LHA
M1
MeP
PFC
PVN
VMH

8 days (n = 6)
Con
OLZ
1.24 ± 0.11
1.03 ± 0.12
1.28 ± 0.10
1.07 ± 0.11
0.71 ± 0.12
0.42 ± 0.10
1.09 ± 0.14
0.81 ± 0.09
0.87 ± 0.07
0.66 ± 0.06
0.90 ± 0.06

1.27 ± 0.11
0.98 ± 0.03
1.12 ± 0.07
1.08 ± 0.09
0.84 ± 0.07
0.53 ± 0.12
0.99 ± 0.07
0.94 ± 0.05
0.90 ± 0.06
0.56 ± 0.09
1.02 ± 0.06

P
value
0.849
0.654
0.232
0.960
0.362
0.525
0.553
0.249
0.509
0.386
0.209

16 days (n = 6)
Con
OLZ
0.72 ± 0.07
0.91 ± 0.08
0.74 ± 0.08
0.69 ± 0.07
0.61 ± 0.04
0.52 ± 0.08
0.89 ± 0.08
0.64 ± 0.05
1.07 ± 0.08
0.50 ± 0.05
0.78 ± 0.06

0.64 ± 0.09
0.62 ± 0.12
0.80 ± 0.09
0.64 ± 0.09
0.48 ± 0.12
0.43 ± 0.11
0.80 ± 0.08
0.50 ± 0.09
0.83 ± 0.13
0.33 ± 0.09
0.51 ± 0.11

P
value
0.479
0.077
0.527
0.685
0.343
0.509
0.475
0.206
0.171
0.135
0.094

36 days (n = 6)
Con
OLZ
0.48 ± 0.04
0.78 ± 0.09
0.45 ± 0.08
0.49 ± 0.05
0.69 ± 0.13
0.63 ± 0.12
0.48 ± 0.07
0.68 ± 0.09
0.51 ± 0.06
0.61 ± 0.15
0.62 ± 0.10

0.57 ± 0.09
0.51 ± 0.10
0.50 ± 0.09
0.52 ± 0.07
0.54 ± 0.07
0.53 ± 0.09
0.58 ± 0.06
0.55 ± 0.07
0.50 ± 0.07
0.59 ± 0.10
0.53 ± 0.11

P
value
0.348
0.064
0.671
0.775
0.355
0.514
0.348
0.323
0.634
0.947
0.587

Abbreviations: AcbC, accumbens nucleus, core; Arc, arcuate hypothalamic nucleus; Cg, cingulate cortex; CPu, caudate putamen; DMH,
dorsomedial hypothalamic nucleus; LHA, lateral hypothalamic area; M1, primary motor cortex; MeP, medial posterodorsal amygdala; PFC,
prefrontal cortex; PVN, paraventricular hypothalamic nucleus; VMH, ventromedial hypothalamic nucleus. Con: control; OLZ: olanzapine.
Statistical significance was defined as p < 0.05.
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2.4 Discussion
The present data suggest that olanzapine-induced weight gain can be divided into
three phases, in which different modulating mechanisms are involved. Excessive food
intake may be the main reason for the rapid increase in body weight in short-term
olanzapine treatment (early stage). This study also demonstrated that the mRNA
expression of HDC, a key enzyme which catalyzes histamine synthesis, was increased
only after short-term olanzapine treatment. The mechanism by which olanzapine has
induced the increase in HDC mRNA expression is not fully understood. It is possible
that olanzapine treatment may lead to a compensatory increase of HDC mRNA
because olanzapine affects histamine neurotransmission through blocking the
postsynaptic H1 receptors (Deng et al., 2010). The H1 receptor antagonists,
pyrilamine, diphenhydramine, triprolidine and terfenadine have been reported to
stimulate histamine release in the rat brain (Fell et al., 2012) and a study in vitro in
mast cells of human lung, skin and tonsil (Okayama et al., 1994). A previous acute
study in rats reported that olanzapine and clozapine dose-dependently (3 mg/kg, and
10 mg/kg but not 1 mg/kg) increases the extracellular histamine level in the prefrontal
cortex, and that this effect was mediated via antagonism of H1 receptors (Fell et al.,
2012). These data suggest that the H1 receptor blockade may lead to a compensatory
increase in histamine release, and this effect may overload the histamine synthesis
pathway (Takahashi et al., 2002). Therefore, in this study, the olanzapine-induced
increase of HDC mRNA may be at least partly associated with H1 receptor
antagonism. It is likely that during short-term treatment, olanzapine blocks the
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postsynaptic H1 receptor and increases H1 receptor binding density, and these effects
may lead to increased histamine synthesis by HDC from L-histidine. Further studies,
for example examining the histamine level in the hypothalamus following olanzapine
treatment, would be helpful. However, Fell et al. (2012) only focus on the acute effect
of olanzapine on central histamine release in rat brain. The effect of long-term
olanzapine treatment on histamine synthesis and release is not known. The present
study demonstrated that during chronic olanzapine treatment, the HDC mRNA
expression no longer increased. These results suggest that hypothalamic histamine
tone may also be affected via other feedback mechanisms such as serotonin 2A
receptor blockade (Morisset et al., 1999). Moreover, the significant correlations
between HDC mRNA and food intake, and HDC and weight gain after 8-day
olanzapine treatment suggest that this change of HDC mRNA may be related to
olanzapine-induced hyperphagia and weight gain. However, we could not exclude the
possibility that the HDC mRNA increase may relate to other effects of olanzapine,
since enhancement of histamine neurotransmission in the brain has also been
suggested to be implicated in the therapeutical effects of antipsychotics (Morisset et
al., 1999, Fell et al., 2012).

The study revealed region-specific changes of the H1 receptor binding in the different
stages of olanzapine-induced weight gain. In the hypothalamus Arc and VMH, a
significantly increased H1 receptor binding was found after olanzapine treatment (3
mg/kg/day). A study in rats demonstrated that clozapine, similar to olanzapine,
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significantly increased the H1 receptor binding in the hypothalamus (Humbert-Claude
et al., 2012). However, the mechanisms by which the H1 receptor binding was
increased by olanzapine and clozapine remain unclear. H1 receptors display
constitutive activity (Bond and Ijzerman, 2006). Treatment with inverse agonists on
receptors with constitutive activity can up-regulate receptor levels (reviewed by
Milligan and Bond (1997)). It is suggested that olanzapine and clozapine may work as
H1 receptor inverse agonists suppressing the internalization of the H1 receptor, which
thus leads to an increased H1 receptor expression (Humbert-Claude et al., 2012).
Moreover, since the antagonism of the G-protein coupled receptors (GPCRs) can
induce an up-regulation of these receptors via a negative feedback mechanism to
maintain the physiological homeostasis of receptor signaling (Ng et al., 1997, Zaki et
al., 2000), it is likely that the olanzapine-induced antagonism of the H1 receptor (a
GPCR) may drive a negative feedback loop to up-regulate H1 receptor expression.

It has been suggested that different neural mechanisms may be involved in the
different stages of olanzapine-induced weight gain (Pai et al., 2012). In this study, an
increased H1 receptor binding in the Arc and VMH has been found in all three stages
of olanzapine-induced weight gain. The significant correlation between H1 receptor
binding and feeding efficiency/weight gain in all three stages suggests that H1
receptor antagonism may play a different role in the different stages of weight gain. It
is well-known that the hypothalamic Arc and VMH control feeding (Morton et al.,
2006, Williams and Elmquist, 2012) and energy expenditure (Kong et al., 2012,
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Williams and Elmquist, 2012). Additionally, in the hypothalamus, activation of the
Arc AMPK increases food intake (Kohno et al., 2011), whilst the activation of VMH
AMPK decreases BAT thermogenesis (Schneeberger and Claret, 2012). Possibly, the
antagonism of the H1 receptors may significantly contribute to olanzapine-induced
hyperphagia and weight gain via activating AMPK signaling in the Arc and VMH.

The hypothalamic H1 receptors are involved in the regulation of energy expenditure,
partly by regulating the sympathetic outflow to BAT (Masaki et al., 2004, Yasuda et
al., 2004, Masaki and Yoshimatsu, 2006, Lundius et al., 2010). SGAs (including
olanzapine) may also decrease energy expenditure by blocking the H1 receptors in the
central nervous system (He et al., 2013). In the present study, at the middle and late
stages of olanzapine-induced obesity, H1 receptor binding was significantly positively
correlated with weight gain. It is possible that during long-term olanzapine treatment,
the antagonism of the hypothalamic H1 receptors may contribute to an olanzapineinduced decrease in energy expenditure and the maintenance of high body weight.

This study has also demonstrated a significant increase in H1 receptor binding in the
DVC after the 16 and 36-day treatments. The DVC H1 receptor expression
significantly correlated (16-day) or tended to correlate (36-day) with weight gain. The
DVC receives both the descending projections from most hypothalamic regions and
gut-derived satiety signaling in feeding regulation (Schwartz, 2006, Blevins and
Baskin, 2010). In addition, the DVC is associated with the modulation of energy
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expenditure (Hayes et al., 2009, Hayes et al., 2011). Consistent with a previous study,
this study found highly expressed H1 receptors in the DVC (Bhuiyan et al., 2011).
The H1 receptors in the NTS regulate arterial pressure and heart rate (Bhuiyan et al.,
2011). However, the role of the DVC H1 receptors in food and body weight regulation
remains unclear. The current study suggests that the DVC H1 receptor may also
contribute to olanzapine-induced weight gain. It has also been reported that the energy
sensor AMPK plays an essential role in body weight regulation in the DVC through
both food intake and energy expenditure (Hayes et al., 2009). Therefore, to investigate
the role of H1 receptor and AMPK in the DVC in olanzapine-induced weight gain is
warranted.

The present study also found an olanzapine-induced increased H1 receptor binding in
the MeP, a region that regulates body weight gain (Rollins and King, 2000). This
change showed a trend to correlation with weight gain. Lesion of the amygdala, in
particular the posterodorsal region (including the MeP and intra-amygdaloid bed
nucleus of the stria terminalis), resulted in increased food intake and obesity in rats
(Rollins and King, 2000). Moreover, the MeP interacts with the hypothalamic VMH
in the modulation of energy balance and body weight (Grundmann et al., 2005). The
long-term antagonism of the H1 receptor (36-day treatment) in the MeP may play a
role in an olanzapine-induced positive energy balance, but further studies are needed.
A study in awake rats reported that the microinjection of histamine in the MeP
increased the sympathetic activity at base conditions and decreased the
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parasympathetic activity (Quagliotto et al., 2008). This suggests that the histamine
system in the MeP may affect homeostatic conditions. However, the role of the MeP
H1 receptor in body weight regulation is poorly understood. Moreover, the H1
receptor in the amygdala is involved in emotional memory (Serafim et al., 2012).
Therefore, we cannot exclude the possibility that the changes in the H1 receptor in the
MeP were related to memory-associated energy balance regulation.

The H3 receptor binding was decreased, albeit non-significantly in the Arc after longterm olanzapine treatment (36 days), which negatively correlated with the weight gain.
The H3 receptor mRNA is abundant in the Arc (Lovenberg et al., 1999). The
significant correlation between the Arc H3 receptor binding and weight gain suggests
that although olanzapine has a very low affinity for the H3 receptor, the Arc H3
receptor may be involved in olanzapine-induced weight gain during long-term
treatment. Hypothalamic H3 receptors are associated with regulation of food intake
and energy expenditure (Takahashi et al., 2002, Malmlof et al., 2005). It has been
reported that H3 receptor knock-out mice are accompanied by hyperphagia, increased
body weight, adiposity, and reduced energy expenditure as well as enhanced
histamine turnover (the tele-methylhistamine) and decreased histamine level
(Takahashi et al., 2002). Therefore, during long-term olanzapine treatment, H3
receptor decrease may partly contribute to the decreased energy expenditure induced
by olanzapine treatment.
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The inhibition of the H3 receptor promotes histamine release, whilst the activation of
the H3 receptor decreases histamine release, as reviewed in Deng et al. (2010).
Olanzapine can increase extracellular histamine level and histamine turnover in the rat
brain (Morisset et al., 1999). Therefore, the olanzapine-induced changes in histamine
levels mentioned above may also be associated with the H3 autoreceptor. To further
investigate the role of the H3 receptor in antipsychotic-induced weight gain, it would
be helpful to examine the hypothalamic histamine release and histamine turnover at
different stages of olanzapine-induced weight gain in future studies. However, H3
heteroreceptors also localize on other monoaminergic terminals, such as serotonergic
neurons, and participate in the control of food intake and energy balance, as reviewed
previously (Deng et al., 2010). As a result, the regulation of body weight by the H3
receptor and its role in olanzapine-induced weight gain may be via several
neurotransmitter systems.

2.5 Summary
Olanzapine treatment time-dependently modulates the histaminergic system. During
short-term treatment, olanzapine increases the expression of HDC mRNA. This might
be associated with olanzapine‘s antagonistic effect on the H1 receptor, and this effect
may be related to olanzapine-induced hyperphagia and weight gain. Short-term
olanzapine treatment also increased the hypothalamic H1 receptor binding, which may
modulate weight gain via the Arc and VMH AMPK signaling. As treatment was
prolonged, olanzapine-induced the elevation of the H1 receptor binding in both the
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hypothalamus and DVC, but did not change the level of HDC mRNA expression. This
suggests the importance of the H1 receptor in all of the stages of olanzapine-induced
weight gain. However, the H3 receptor appears to relate to olanzapine-induced weight
gain during long-term treatment. Therefore, the modulation of the histaminergic
system may shed light on the treatment of olanzapine-induced weight gain during
both short- and long-term treatment.
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CHAPTER 3

HYPOTHALAMIC HISTAMINE H1 RECEPTOR-AMPK SIGNALING TIMEDEPENDENTLY MEDIATES OLANZAPINE-INDUCED HYPERPHAGIA
AND WEIGHT GAIN IN FEMALE RATS

This Chapter was published in He, M., Zhang Q., Deng, C., Wang H.Q., Lian J.,
Huang, X.F., 2014. Hypothalamic histamine H1 receptor-AMPK signaling timedependently mediates olanzapine-induced hyperphagia and weight gain in female rats.
Psychoneuroendocrinology 42, 153-164

3.1 Introduction
Antipsychotic-induced obesity is a serious side effect and requires a systematic and in
depth understanding of the molecular mechanisms involved in the progressive
development of obesity in order to develop appropriate therapeutic strategies. In the
clinic, antipsychotics‘ affinity for the H1 receptor predicts (Kroeze et al., 2003) and
correlates (Matsui-Sakata et al., 2005) with antipsychotic-induced weight gain. In rats,
olanzapine treatment alters H1 receptor mRNA expression in the hypothalamus,
which is negatively correlated with weight gain (Han et al., 2008). Therefore, the H1
receptor antagonism appears to be a key factor in olanzapine-induced obesity (Deng et
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al., 2010, He et al., 2013). In fact, betahistine (an H1 receptor agonist/ H3 receptor
antagonist) has been used to prevent olanzapine-induced weight gain in humans
(Poyurovsky et al., 2005, Poyurovsky et al., 2012) and rats (Deng et al., 2012).

Hypothalamic AMP-activated protein kinase (AMPK) regulates food intake. It has
been reported that histamine decreases pAMPK, which can be reversed by clozapine
in mouse hypothalamic slices (Kim et al., 2007). Furthermore, clozapine-induced
hypothalamic AMPK activation was abolished in H1 receptor knock-out mice (Kim et
al., 2007). Other investigators have reported that hypothalamic AMPK is activated by
olanzapine (Martins et al., 2010, Sejima et al., 2011, Skrede et al., 2013). These data
suggest a possibility that olanzapine may also activate the hypothalamic AMPK via
the H1 receptor blockade, which may play a role in olanzapine-induced weight gain

As has been discussed in Chapter 1 and 2, evidence from both clinic and animal
models has suggest that olanzapine-induced weight gain may occur in three stages:
early acceleration stage (human: first 3 months; rats: first 2 weeks); middle new
equilibrium stage (human 3-18 months; rats: week 3-4); and late heavy weight
maintenance stage (human:> 18 months, rats: week 5) (Allison and Casey, 2001,
Huang et al., 2006, Pai et al., 2012). These evidence suggest that different neural
mechanisms may be involved in different stages of olanzapine-induced weight gain.
Therefore, two key questions are: does hypothalamic H1 receptor-AMPK signaling
play a different role in the different stages of olanzapine–induced obesity; and is H1
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receptor-AMPK signaling a potential target for treating olanzapine-induced obesity?
This study provides evidence for the first time that the time-dependent modulating
mechanisms of hypothalamic H1 receptor-AMPK signaling underlie the three
developmental stages of olanzapine-induced obesity. The effect of central H1 receptor
activation in reducing olanzapine-induced hyperphagia and its relationship with
AMPK signaling in the hypothalamus have been tested.

3.2 Materials and methods
3.2.1 Animals and housing
The same rats and housing that were described in Chapter 2 were used in the present
study.

3.2.2 Experiment one
To investigate the role of hypothalamic H1 receptor-AMPK signaling at the three
stages of olanzapine-induced weight gain, this experiment was conducted to detect
changes of the H1 receptor-AMPK signaling under olanzapine treatment for 8, 16 and
36 days. The same rats and olanzapine treatment procedures that were described in
Chapter 2 were used in the present study. For western blot and real-time PCR, the rats
were sacrificed 2 hours after last drug treatment using CO2 asphyxiation (0900 h to
1100 h). The brains were immediately collected. The hypothalami were quickly
dissected on ice, frozen in liquid nitrogen and then stored at -80 °C.
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3.2.3 Experiment two
To address the question of whether direct activation of central H1 receptors could
reduce olanzapine-induced hyperphagia, and whether this effect is linked to
hypothalamic AMPK signaling, olanzapine-treated rats were given an icv injection of
an H1 receptor agonist. After acclimatization, each SD rat was surgically implanted
with a 24-gauge guide cannula into the lateral ventricle under isoflurane anesthesia
(1.0 mm posterior to the bregma, 1.5 mm lateral to the midline, and 3.5 mm below the
top skull) (Paxinos and Watson, 2007). After one week recovery, the rats were orally
treated with olanzapine or vehicle (same as in Experiment one) for 4 days. On day 5,
the rats received 0, 100 or 200 nmoles (Lecklin et al., 1998) icv injection of the H1
receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH, purchased from
sigma), or saline (n = 5-8/group) at a rate of 5 µl/min, and the volume was 5 µl
(Group 1, vehicle/saline; Group 2, vehicle/FMPH 200 nmoles; Group 3,
olanzapine/saline;

Group

4,

olanzapine/FMPH

100

nmoles;

Group

5,

olanzapine/FMPH 200 nmoles). Thirty minutes later, the rats were treated orally with
olanzapine at the same dose or with the vehicle. Food intake in all rats was measured
at 1, 2, 4, 16 (overnight) and 24h after the olanzapine or vehicle administration. To
test whether the suppressive effect of FMPH 200 nmoles on food intake in
olanzapine-treated rats could be reversed by H1 receptor antagonism, the rats were
given an icv injection of pyrilamine (800 nmoles) before FMPH was given, and then
food intake was tested (Group 6, olanzapine/FMPH 200 nmoles/pyrilamine 800
nmoles).To further examine the role of H1 receptor-AMPK signaling in olanzapine68

induced hyperphagia, the same treatment was repeated after a three day drug washout
period. Rats were then sacrificed using CO2 asphyxiation 1 h after their last treatment
(between 1200 h and 1400 h) to detect H1 receptor-AMPK signaling in the
hypothalamus. The hypothalamic nuclei were identified and dissected according to the
standard rat brain atlas (Paxinos and Watson, 2007). Briefly, rat brains were snapfrozen, cut at 500 µM coronal sections from Bregma -2.16 mm to -3.60 mm, -1.44
mm to -2.04 mm, and -2.16 mm to -3.60 mm, for arcuate nucleus (Arc),
paraventricular nucleus (PVN) and lateral hypothalamic area (LHA) respectively. The
temperature was set at -18°C. The nuclei were dissected using micro-punches
(#57401, Stoelting Co, Wood Dale, IL, USA) (Zhang et al., 2014a). The Arc was
dissected in an overlapping pattern over the third ventricle. Since the Arc is small, the
punched tissue primarily contained Arc, but the inclusion of adjacent brain areas
cannot be ruled out, therefore the punched tissue containing Arc was named as the
MBH.

3.2.4 Real-time quantitative PCR
Real-time quantitative PCR was used to detect the mRNA expression of the H1
receptors, AMPKα, ACCα (a downstream target of AMPK), corticotrophin-releasing
hormone (CRH), leptin receptor and orexin-A, NPY and AgRP: H1 receptor (assay
no. Rn00566691_s1); AMPKα2 (assay no. Rn00576935_m1); ACCα (assay no.
Rn00573474_m1), CRH (assay no. Rn01462137_m1); leptin receptor (assay no.
Rn01433205_m1), NPY (Rn00821417_m1), AgRP (Rn01431703_g1) and orexin-A
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(assay no. Rn00565995_m1). Details regarding the procedure of real time PCR are
outlined in Chapter 2.

3.2.5 Western blot
Western blot was performed following the procedure previously described (du Bois et
al., 2012). Tissues were homogenized in NP40 cell lysis buffer (Life Technologies)
containing

a

protease

inhibitor

cocktail,

beta-glycerophoshate

and

phenylmethanesulfonyl fluoride (Sigma, NSW, Australia). Protein concentration was
detected by DC protein assay (Bio-Rad Laboratories, Gladesville, Australia). Proteins
were loaded onto 4-12% Bis-Tris gels (Bio-Rad). Following electrophoresis for 50
min at 200V, the proteins were transferred to polyvinylidene difluoride (PDVF)
membranes (100V for 1h) (Bio-Rad). Membranes were then blocked for 1h in 5%
bovine serum albumin (BSA) in tris buffered saline with 0.1% Tween 20 (TBST) and
incubated with the primary antibodies in 1% BSA at 1:1000 overnight at 4°C. Primary
antibodies were: AMPKα, ACC, pAMPKα (Cell Signaling Technology, Danvers, MA,
USA) and pACCα (Millipore, Billerica, MA, USA). Following washing in TBST
(3×5min), membranes were incubated with the goat anti-rabbit (1:5000 Santa Cruz
Biotechnologies, Santa Cruz, CA, USA), and horseradish peroxidase conjugated
secondary antibody for 1h at 25°C. Immunoractive proteins were detected using the
enhanced chemiluminescence (ECL) kit (GE Healthcare, Rydalmere, NSW,
Australia). The results were quantified using Bio-Rad Quantity One software. The
quantification was normalized to β-actin, according to previous studies (Ferno et al.,
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2011).

3.2.6 Statistics
The statistics were performed using the SPSS 19.0 program (Chicago, IL, USA). In
experiment one, the differences in feeding efficiency, H1 receptor, AMPKα and ACCα
mRNA expression, AMPKα, ACC, pAMPKα and pACCα protein expression, leptin
and insulin levels were analyzed using an independent unpaired student t-test (twotailed). Where data were not normally distributed, non-parametric tests (Kruskal–
Wallis H test followed by Mann–Whitney U tests) were undertaken in place of t-tests
and ANOVA. In Experiment two, Kruskal–Wallis H test followed by Mann–Whitney
U tests were used to compare the difference in food intake, the hypothalamic leptin
receptor, orexin-A, corticotrophin-releasing hormone (CRH) and NPY and AgRP
mRNA expression following the icv injection. One-way ANOVA followed by post
hoc Tukey‘s multiple comparison were used to analyze the statistical differences of
pAMPKα and pACCα expression in different hypothalamic regions. Correlations
were identified using Pearson‘s correlation. All data were presented as mean ± SEM.
Statistical significance was defined as p ≤ 0.05.
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3.3 Results

3.3.1 Hyperphagia contributed to rapid weight gain in the early stage of
olanzapine-induced obesity
As has been shown in Chapter 2 Results 2.3.1, olanzapine-induced weight gain in the
female rats occurred in three stages: olanzapine treatment induced a significant
elevation in 48 h food intake only during the first 12 days, accompanied by a rapid
weight gain. The data suggests that elevated food intake largely contributes to short
term olanzapine-induced weight gain (early stage). To confirm the relationship
between food intake and body weight in the different stages of weight gain, feeding
efficiency (grams of weight gained/grams of food consumed) was also calculated. At
the early stage, the feeding efficiency significantly increased in the olanzapine-treated
group compared with the control group (control vs. olanzapine: 0.034 ± 0.004 vs.
0.049 ± 0.002, p = 0.007, Student‘s t test). In the middle and late stages, the feeding
efficiency of the olanzapine-treated rats was not significantly different to that of the
control group (middle stage: control vs. olanzapine: 0.021 ± 0.001 vs. 0.018 ± 0.004,
p = 0.480; late stage: 0.013 ± 0.003 vs. 0.018 ± 0.007, p = 0.552, Student‘s t test).

3.3.2. Olanzapine induced time-dependent changes of hypothalamic H1 receptorAMPK signaling differing in the three stages of obesity development
In order to investigate the role of hypothalamic H1 receptor-AMPK signaling in
olanzapine-induced obesity, rats were treated with olanzapine for 8, 16 and 36 days to
represent the three stages of olanzapine-induced weight gain. In the early stage (8-day
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treatment), olanzapine treatment induced a significantly elevated hypothalamic H1
receptor mRNA expression (125 ± 7%, p = 0.015 vs. control, n = 5/group, Student‘s t
test) but an unchanged AMPKα2 and acetyl-CoA carboxylase α (ACCα, a
downstream target of AMPK) mRNA expression compared to the control rats (Figure
3.1A). The hypothalamic pAMPKα expression (activated AMPK) but not pACCα
expression was significantly increased by olanzapine (Figure 3.2 A, B; 124 ± 8%, p =
0.021; 119 ± 12%, p = 0.354, respectively, n = 5-6/group, Student‘s t test).
Importantly, Pearson‘s correlation revealed that the pAMPKα and pACCα expression
were positively correlated with H1 receptor mRNA expression as well as the last 48h
food intake (Table 3.1). These data suggest that olanzapine-induced hyperphagia and
weight gain are associated with the activation of AMPK via a blockade of H1 receptor
by olanzapine.
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Figure 3.1 Effects of olanzapine on the gene expressions of hypothalamic H1
receptor-AMPK signaling after 8- (A, early stage), 16- (B, middle stage) and 36-day
(C, late stage) olanzapine treatments (n = 5-6/group). All data are presented as mean ±
SEM. Statistical significance was defined as p < 0.05 (* p < 0.05 vs. control).

In the middle stage (16-day treatment), when the rats were no longer hyperphagic,
both the changes in H1 receptor mRNA expression and pAMPKα and pACCα protein
expression vanished (Figure 3.1B, Figure 3.2 A and C). At this stage, changes of
pAMPK and pACC were not significantly correlated with the last 48h food intake or
weight gain (Table 3.1). In the late stage (36-day treatment), olanzapine significantly
increased hypothalamic H1 receptor mRNA expression (130% ± 5, p = 0.046,
Student‘s t test) compared to the control rats (Figure 3.1C). The H1 receptor mRNA
expression was significantly positively correlated with weight gain (r = 0.712, p =
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0.016; Table 3.1). However, both the ACCα mRNA expression (Figure 3.1C; 80 ± 6%,
p = 0.030, Student‘s t test) and the pAMPKα and pACCα protein expression were
significantly decreased compared with the control rats (Figure 3.2 A, D; 84 ± 1%, p =
0.005; 79 ± 5%, p = 0.023, respectively, Student‘s t test). Notably, the pAMPKα
expression was negatively correlated with H1 receptor mRNA expression and weight
gain (Table 3.1). These data suggest that as olanzapine treatment was prolonged,
AMPK activity declined and was less effective in up-regulating food intake. Since
hypothalamic AMPK can also be inhibited by leptin and insulin (Minokoshi et al.,
2004), the plasma leptin and insulin levels of rats with late stage olanzapine-induced
obesity were measured. These rats had significantly increased plasma leptin than the
control group (control vs. olanzapine: 8.4 ± 1.8 vs. 15.0 ± 1.5 ng/ml; p = 0.027, n =
6/group, Student‘s t test). Their insulin level was not significantly different (control
vs. olanzapine: 1.2 ± 0.4 vs. 1.5 ± 0.3 ng/ml; p = 0.158, n = 6/group, Student‘s t test).
These results suggest that leptin may be involved in inhibiting AMPK signaling at the
late stage of olanzapine-induced obesity.
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Figure 3.2 Effects of olanzapine on the protein expressions of hypothalamic AMPK
signaling after 8- (early stage), 16- (middle stage) and 36-day (late stage) olanzapine
treatments (n = 5-6/group). A, Western blot of representative samples after 8-, 16- and
36-day olanzapine or vehicle treatment, displaying bands of AMPKα, pAMPKα,
ACC, pACCα and actin expression in the hypothalamus. B, C, D, Western blot
analysis of the protein expression of hypothalamic AMPKα, pAMPKα, ACC and
pACCα after 8-, 16- and 36-day olanzapine treatment. All data are presented as mean
± SEM. Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 0.01 vs.
control).
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Table 3.1 Correlations within the hypothalamic H1 receptor mRNA, pAMPKα and pACCα protein expression, food intake and weight gain
during the three stages of olanzapine-induced obesity.
8 days

16 days

36 days

pAMPKα

pACCα

pAMPKα

pACCα

pAMPKα

pACCα

r (P-value)

r (P-value)

r (P-value)

r (P-value)

r (P-value)

r (P-value)

-0.798 (0.002**)

-0.639 (0.025*)

H1R mRNA

0.718 (0.029*) 0.647 (0.043*) -0.057 (0.875)

0.226 (0.505)

Last 48h FI

0.747 (0.021*) 0.647 (0.031*) 0.281 (0.431)

-0.119 (0.713) -0.225 (0.482)

0.117 (0.718)

Weight gain

0.717 (0.030*) 0.324 (0.332)

0.159 (0.640)

-0.230 (0.447)

pAMPKα

0.691(0.027)

-0.432 (0.245)

0.160 (0.659)

-0.743 (0.009**)

0.585 (0.046*)

Abbreviations: FI: food intake; H1R: histamine H1 receptor; pACCα, acetyl CoA carboxylase phosphorylated Ser79 at ACCα subunits;
pAMPKα, AMP-activated protein kinase phosphorylated Thr172 at AMPKα subunits. Statistical significance was defined as p < 0.05 (* p <
0.05, ** p < 0.01). Significant correlations are indicated in bold.
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3.3.3 Histamine H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine,
attenuated olanzapine-induced hyperphagia
Having observed the importance of the central H1 receptor-AMPK signaling in
olanzapine-induced weight gain, we further investigated whether the direct activation
of the central H1 receptors could reduce olanzapine-induced hyperphagia and weight
gain. The H1 receptor agonist, 2-(3-trifluoromethylphenyl) histamine (FMPH), was
injected into the lateral brain ventricle of rats treated with either olanzapine or vehicle
for five days. Olanzapine treatment significantly increased food intake and cumulative
body weight gain from day 2 (Figure 3.3A and B). Rats on olanzapine treatment
followed by an icv injection of saline (controls) showed a significant increase in food
intake in 1, 2, 4 and 16 h at 85%, 112%, 61%, 19%, respectively (Figure 3.3C; all p <
0.05 vs. vehicle/saline, Mann-Whitney U test). This effect was significantly
attenuated by central FMPH treatment from 1 to 16 h time points (Figure 3C;
Kruskal-Wallis H test for each time points: 1 h: H(5) = 13.251, p = 0.021; 2 h: H(5) =
11.121, p = 0.049; 4 h: H(5) = 15.954, p = 0.007; 16 h: H(5) = 10.957, p = 0.052; 24
h: H(5) = 8.139, p = 0.149, n = 5-8/group). Olanzapine-induced hyperphagia was
reduced by 64%, 51%, 44%, 21%, respectively as measured at 1, 2, 4 and 16 h by
FMPH 200 nmoles (all p < 0.05 vs. olanzapine/saline, Mann-Whitney U test). The
inhibitory effect of FMPH 100 nmoles was also evident, with the most significant
changes found in 4 and 16 h at 42% and 28%, respectively ( p = 0.003, p = 0.073 vs.
olanzapine/saline, Mann-Whitney U test). However, the FMPH 200 nmoles injection
did not significantly reduce food intake at any time points tested compared with the
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controls (all p > 0.05 vs. vehicle/saline, Mann-Whitney U test). We also investigated
whether blocking the H1 receptor could reverse the effect of FMPH on food intake in
olanzapine-induced hyperphagia, by treating rats with pyrilamine 800 nmoles (an H1
receptor antagonist) before FMPH was given. However, pyrilamine 800 nmoles was
not able to reverse the effect of FMPH on food intake at all-time points (all p > 0.05
vs. olanzapine/FMPH 200nmols, Mann-Whitney U test). These data suggest that the
activation of the central H1 receptor is effective for treating olanzapine-induced
weight gain.
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Figure 3.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on olanzapine-induced increased food
intake (n = 5-8/group). A and B, Food intake and cumulative body weight gain of the
rats treated with olanzapine significantly increased from day 2. C, FMPH dosedependently inhibited olanzapine-induced hyperphagia at different time points. All
data are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (*
p < 0.05, ** p < 0.01). H, high dose; L: low dose; PY: pyrilamine; V/S, vehicle/saline;
V/F(H),

vehicle/FMPH

200

nmoles;

O/S,

olanzapine/saline;

O/F(L),

olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY,
olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles.
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3.3.4 FMPH treatment inhibited olanzapine-induced AMPK activation in the
hypothalamic MBH
To understand the mechanisms by which FMPH attenuated olanzapine-induced
hyperphagia, the dose dependent effect of FMPH on AMPK signaling in olanzapinetreated rats has been investigated. We examined the effect of olanzapine and FMPH
on AMPK signaling in specific hypothalamic regions including the MBH and
paraventricular nucleus (PVN) as these regions are significantly involved in H1
receptor (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et al., 1989, Umehara et
al., 2010) and AMPK (Lage et al., 2008, Lopez et al., 2008) regulation of food intake.
In the MBH, it has been found that olanzapine treatment significantly increased
pAMPKα (127 ± 8% vs. vehicle/saline) and pACCα (134 ± 9% vs. vehicle/saline)
expression compared with the vehicle-treated rats (Figure 3.4A, B; ANOVA, F(5,28) =
2.867, p = 0.033; F(5,31) = 4.312, p = 0.004, respectively, n = 5-7/group, Tukey post
hoc tests). Injecting 200 nmoles FMPH significantly decreased pAMPKα and pACCα
expression compared with saline in the olanzapine-treated rats (101 ± 3%, p = 0.040;
99% ± 6%, p = 0.046, respectively, Tukey post hoc tests). FMPH 100 nmoles did not
attenuate the olanzapine-induced activation of pAMPKα (110 ± 5%) and pACCα (127
± 8%) in the MBH (p > 0.05, Tukey post hoc tests). Consistent with food intake data,
the pyrilamine treatment did not significantly reverse the suppressive effect of FMPH
on hypothalamic pAMPKα (107 ± 6%) and pACCα (101 ± 9%) in olanzapine-treated
rats (p > 0.05, Tukey post hoc tests). It was noted that the pAMPKα expression
positively correlated with food intake at 1h (Table 3.2). These data suggest that the
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central activation of the H1 receptors reduced the olanzapine-induced food intake,
probably via the inhibition of MBH AMPK signaling. However, in the PVN,
olanzapine treatment did not significantly increase the pAMPKα and pACCα
expression compared with vehicle (Figure 3.4C).

3.3.5 FMPH increased the mRNA expression of CRH in the PVN in olanzapinetreated rats
The histaminergic system is associated with CRH, leptin and orexin-A in body weight
regulation (Gotoh et al., 2005, Jorgensen et al., 2005). Therefore we examined the
effect of olanzapine and FMPH on hypothalamic CRH, leptin receptor and orexin-A
expression 1 h after the last drug treatment. A previous study showed that olanzapine
reduces CRH release under the condition of K(+)-stimulation (Tringali et al., 2009).
In the present study (Figure 3.5A), olanzapine did not significantly decrease PVN
CRH mRNA expression (60 ± 10% vs. vehicle/saline group, p > 0.05, n = 4-6/group,
Kruskal-Wallis H test followed by Mann-Whitney U test). However, CRH mRNA
expression was significantly increased by both FMPH 200 nmoles and FMPH 100
nmoles compared with the olanzapine/saline group (172 ± 37%, p = 0.033; 88 ± 6%, p
= 0.043, respectively, Mann-Whitney U test). Compared with the vehicle/saline
group, a single injection of 200 nmoles FMPH did not significantly increase CRH
mRNA expression (147 ± 28%, p = 0.251, Mann-Whitney U test). In addition,
olanzapine decreased the expression of the leptin receptor in the MBH (86 ± 3% vs.
vehicle/saline, p = 0.028, n = 4-6/group, Kruskal-Wallis H test followed by Mann82

Whitney U test) compared with the vehicle, and this decrease could not be reversed
by 200 nmoles or 100 nmoles FMPH (Figure 3.5B). The histaminergic system
innervates the orexin-A system associated with food intake and body weight
regulation (Gotoh et al., 2005, Jorgensen et al., 2005). However, orexin-A mRNA
expression was not changed by either the 5 day olanzapine treatment or the central
acute administration of FMPH (Figure 3.5C).

Neuropeptides in the hypothalamus including NPY and AgRP are also important
parameters in causing olanzapine-induced weight gain (Ferno et al., 2011). Therefore,
the effect of olanzapine and FMPH on the expression of MBH NPY and AgRP has
been investigated 1 h after the last drug treatment. Olanzapine treatment for 5 days
significantly increased MBH NPY and AgRP mRNA expression (Figure 3.5D, E; 154
± 14%, p = 0.011; 137 ± 20%, p = 0.050, respectively, Mann-Whitney U test).
However, both 200 and 100 nmoles FMPH did not significantly attenuate the
increased NPY (Figure 3.5D; 122 ± 14%, p = 0.221; 137 ± 13%, p = 0.142, MannWhitney U test) or AgRP (Figure 3.5E; 112 ± 4%, p = 0.213; 119 ± 23%, p = 0.670,
Mann-Whitney U test) mRNA expression induced by olanzapine.
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Figure 3.4 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on the hypothalamic AMPK signaling in
olanzapine or vehicle-treated rats (n = 5-7/group). A and B, Representative western
blot and densitometry analysis of pAMPKα and pACCα expression in the mediobasal
hypothalamus of the olanzapine or vehicle-treated rats receiving the icv injection of
FMPH or saline. C, Western blot analysis of protein expression of pAMPKα and
pACCα in the hypothalamic PVN. All data are presented as mean ± SEM. Statistical
significance was defined as p < 0.05 (* p < 0.05; ** p <0.01). Abbreviations: V/S,
vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L),
olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY,
olanzapine/FMPH

200

nmoles/pyrilamine

800

nmoles.

MBH,

mediobasal

hypothalamus; PVN, paraventricular nucleus.
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Table 3.2 Correlations within the MBH pAMPKα and pACCα protein expression and
food intake during FMPH and olanzapine treatment.

Food intake (1h)
r (P-value)
pAMPKα

0.694 (0.000**)

pACCα

0.240 (0.179)

MBH

Abbreviations: pACCα, acetyl CoA carboxylase phosphorylated at Ser79 at ACCα
subunits; pAMPKα, AMP-activated protein kinase phosphorylated Thr172 at AMPKα
subunits; MBH, mediobasal hypothalamus. Statistical significance was defined as p <
0.05 (**, p < 0.01). Significant correlations are indicated in bold.
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Figure 3.5 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on mRNA expressions of: CRH in the
PVN (A), leptin receptor in the MBH (B), orexin-A in the LHA (C), NPY (D), and
AgRP (E) in the MBH in either olanzapine or vehicle-treated rats (n = 4-6/group). All
data are presented as mean ± SEM. Statistical significance was defined as p ≤ 0.05 (*
p ≤ 0.05). V/S, vehicle/saline; V/F(H), vehicle/FMPH 200 nmoles; O/S,
olanzapine/saline; O/F(L), olanzapine/FMPH 100 nmoles; O/F(H), olanzapine/FMPH
200 nmoles; O/F(H)/PY, olanzapine/FMPH 200 nmoles/pyrilamine 800 nmoles. CRH,
corticotropin-releasing hormone; LHA, lateral hypothalamic area; MBH, mediobasal
hypothalamus; PVN, paraventricular nucleus.
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3.4 Discussion
This study demonstrated different roles of the hypothalamic H1 receptors and AMPK
signaling in the three different stages of olanzapine-induced obesity development. In
the early stage, in accordance with olanzapine-induced hyperphagia, increased
hypothalamic H1 receptor mRNA expression and activated AMPK signaling was
found. Positive correlations were also shown between the pAMPK level and H1
receptor mRNA, food intake, and weight gain. This suggests that olanzapine activates
AMPK by blocking the H1 receptors in olanzapine-induced hyperphagia and body
weight gain. This was supported by a further test that a single icv injection of an H1
receptor agonist significantly attenuated olanzapine-induced hyperphagia and AMPK
activation. Coinciding with these findings, previous studies also reported the
activation of hypothalamic AMPK by olanzapine treatment (< 2 weeks) (Sejima et al.,
2011, Skrede et al., 2013). Although one study showed that short-term olanzapine
treatment inhibited hypothalamic AMPK activity (Ferno et al., 2011), their
measurement of AMPK was done 20 h after the last drug treatment, and thus the
inhibition of pAMPK may be due to the negative feedback mechanism caused by high
body weight rather than being a direct effect of olanzapine.

As treatment was prolonged, alterations of hypothalamic H1 receptor-AMPK
signaling vanished (middle stage), followed by increased H1 receptor mRNA
expression but decreased pAMPK protein expression (late stage). The fact that AMPK
phosphorylation returned to normal and was then inhibited suggests that AMPK acts
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as an energy sensor by negatively responding to positive energy balance.
Hypothalamic AMPK activity is also inhibited by insulin and leptin (Minokoshi et al.,
2004, Lopez et al., 2008). In the present study, an increased plasma level of leptin in
the late stage of olanzapine-induced obesity has been found. This may contribute to
the down-regulation of hypothalamic AMPK signaling. In fact, it has been suggested
that the combined effects of hyperinsulinemia and increased leptin secretion may lead
to the inhibition of hypothalamic AMPK activity in mice with diet-induced obesity
(Martin et al., 2006, Viollet et al., 2010).

During chronic olanzapine treatment, the continuous weight gain without hyperphagia
indicated that other factors besides AMPK may also be involved in olanzapineinduced weight gain. Possibly, the decreased energy expenditure may largely account
for the increase in weight gain especially at the later stages (Stefanidis et al., 2008,
Cuerda et al., 2011). However, in the case of late stage olanzapine-induced obesity,
both hypothalamic pAMPK and its directly downstream target pACC expression were
decreased. This evidence indicates that hypothalamic AMPK may drive a negative
energy balance which is not strong enough to reduce the weight gained after chronic
olanzapine treatment, although the exact mechanism for the maintenance of heavy
weight in the late stage still requires further study. In fact, other studies have shown
that AMPK signaling is decreased in diet-induced obesity in rodents, including the
whole mouse and rat hypothalamus (Fei et al., 2012, Whittle et al., 2012) and the
mouse hypothalamic PVN (Martin et al., 2006). Similarly, the current study showed
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decreased hypothalamic AMPK signaling in obese rats induced by chronic olanzapine
treatment. In addition, data have reported that long-term olanzapine treatment is
associated with decreased BAT temperature, BAT uncoupling protein 1 (UCP-1)
expression (Stefanidis et al., 2008, Zhang et al., 2013a) and peroxisome proliferator
activated coactivator 1α (PGC-1α) (Zhang et al., 2013a). These results could be a
direct effect of olanzapine on BAT via lowering sympathetic activity in the late stage.
This can occur independently of its effect on hypothalamic AMPK signaling.

H1 receptor antagonism plays a role in reducing energy expenditure and maintaining a
high body weight during long-term olanzapine-induced weight gain (Masaki et al.,
2004, Yasuda et al., 2004, Masaki and Yoshimatsu, 2006, Lundius et al., 2010). In the
present study, at the late stage of olanzapine-induced obesity, H1 receptor mRNA was
increased, and the H1 receptor mRNA expression was significantly positively
correlated with weight gain. It is possible that the H1 receptors may contribute to an
olanzapine-induced decrease in energy expenditure and the maintenance of high body
weight during the middle and late stages. Additionally, future studies on the effect of
olanzapine on browning markers on white adipose tissue would be helpful (Fisher et
al., 2012). Since chronic olanzapine treatment also increases subcutaneous and
visceral white adipose tissue (Weston-Green et al., 2011), it is desirable to examine
whether olanzapine treatment affects the expression of fat storage enzymes such as
lipoprotein lipase and fatty acid synthesis in inguinal subcutaneous and visceral white
adipose tissue.
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The mechanisms by which olanzapine up-regulates H1 receptor mRNA expression
remains unknown. As has been discussed in Chapter 2, the increased expression of H1
receptor may be associated with the constitutive activity of the H1 receptor.
Olanzapine, similar to clozapine, may work as an inverse agonist of the H1 receptors
which suppress the H1 receptor internalization, which in turn results in H1 receptor
up-regulation (Humbert-Claude et al., 2012). Or it could be possible that the increased
H1 receptor mRNA expression was due to a negative feedback loop of the H1
receptor antagonism.

This study demonstrated that central H1 receptor activation attenuated olanzapineinduced excessive food intake, supporting the statement that central H1 receptor
antagonism contributes to olanzapine-induced hyperphagia, and could be a potential
target for the treatment of olanzapine-induced obesity. Furthermore, the activation of
AMPK in the MBH by olanzapine was attenuated by the H1 receptor agonist. These
findings suggest that AMPK acts as a downstream target in H1 receptor-regulated
food intake in the MBH, and this nucleus-specific activation of AMPK may be of
major importance in contributing to olanzapine-induced hyperphagia. Further studies
that directly inject the H1 receptor agonist into the Arc are required to confirm the
role of Arc H1 receptor-AMPK signaling in olanzapine-induced hyperphagia and
weight gain. The H1 receptors and AMPK in the PVN are also well-known for their
role in regulating food intake (Sakata et al., 1988, Fukagawa et al., 1989, Ookuma et
al., 1989, Ookuma et al., 1993). However, the lack of AMPK activation in the PVN in
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the present study suggests that PVN H1 receptor-AMPK signaling is unlikely to
contribute to short-term olanzapine-induced hyperphagia and weight gain.

Histamine/H1 receptor signaling can influence the CRH, leptin and orexin systems in
food intake and body weight regulation (Gotoh et al., 2005, Jorgensen et al., 2005).
CRH originating from the PVN exerts an anorexic effect and can be activated by
histamine (Kjaer et al., 1994). The H1 receptor agonist, 2-thiazolylethylamine (2TEA), increased CRH expression in the PVN, suggesting that activating H1 receptors
may also regulate food intake via CRH (Kjaer et al., 1992, Kjaer et al., 1998). The
current study found that the injection of an H1 receptor agonist dose-dependently
increased CRH expression compared with saline in olanzapine-treated rats, suggesting
that the CRH may also act as a downstream hormone of histamine H1 receptor
signaling in olanzapine-induced obesity, however further studies are needed. Since the
Arc is responsible for leptin signaling in the regulation of energy balance, the
decreased leptin receptor expression in the MBH by olanzapine treatment may induce
a resistance to leptin (Panariello et al., 2012). In addition, one study suggested that
orexin is involved in antipsychotic-induced weight gain (Fadel et al., 2002). However,
the present study did not show any change in orexin-A in the LHA under olanzapine
or FMPH treatment. Moreover, this study found an increased expression of NPY and
AgRP in the MBH. This is consistent with previous (Ferno et al., 2011, Zhang et al.,
2014a) and supports the important role of NPY and AgRP in olanzapine-induced
weight gain. However, the olanzapine-induced increase of NPY and AgRP cannot be
91

completely reversed by a single injection of the H1 receptor agonist. This suggests
that the H1 receptor plays a partial role in the olanzapine-induced elevation of NPY
and AgRP.

3.5 Summary
In conclusion, the present data have demonstrated that the effect of olanzapine on
hypothalamic H1 receptor–AMPK signaling varies during the different stages of
obesity development. At the early stage, olanzapine activated hypothalamic AMPK
signaling by blocking the H1 receptors leading to hyperphagia. With a prolonged
treatment, the rats became obese although the excessive food intake was no longer
present, suggesting that other parameters in addition to food intake may also
contribute to increased body weight. It is possible that olanzapine affects other
pathways related to metabolic regulation besides AMPK (Schmidt et al., 2013).
However, we cannot exclude other unknown feedback mechanisms may also
contribute to the results observed in the present study. In summary, the results of this
study may shed light on the future pharmacological development of targeting the H1
receptor–AMPK signaling to assist in minimizing the weight gain side effect of
olanzapine treatment.
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CHAPTER 4

OLANZAPINE-ACTIVATED AMPK SIGNALING IN THE DVC IS
ATTENUATED BY CENTRAL H1 RECEPTOR AGONIST INJECTION IN
FEMALE RATS

This section was published in He, M., Zhang Q., Deng, C., Wang H.Q. and Huang,
X.F., 2014 Olanzapine-activated AMP-activated protein kinase signaling in the dorsal
vagal complex is attenuated by histamine H1 receptor agonist in female rats.
Endocrinology 155 (12):4895-4904.

4.1 Introduction
The DVC, comprising NTS, DMV and AP, is well-known for mediating appetite by
responding to satiety signals. The NTS integrates the signals between the
hypothalamus and the gut to regulate food intake (Schwartz, 2006, Blevins and
Baskin, 2010). The DMV contains primary efferents to regulate the gut and mediates
food intake (Cone, 2005, Zhang et al., 2013b). Previous studies in rats have reported
that the DVC is involved in mediating olanzapine-induced weight gain (Deng et al.,
2007, Weston-Green et al., 2008).

AMPK is a sensor of cellular energy status, which is activated by the cellular
AMP/ATP ratio and upstream kinases (Minokoshi et al., 2004). AMPK in the NTS
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mediates food intake and body weight (Hayes et al., 2009, Hayes et al., 2011). AMPK
activity in the NTS is increased in food-deprived rats, and abolished by refeeding
(Hayes et al., 2009). Inhibition of AMPK by compound C in the NTS reduces food
intake (Hayes et al., 2009). However, whether DVC AMPK signaling plays a role in
mediating olanzapine-induced food intake and weight gain is unknown. Moreover,
both clinical evidence and the present study using animal models (Chapters 2 and 3)
have indicated the time-dependent development of olanzapine-induced weight gain
(early, middle and late stage). Therefore, DVC AMPK signaling may play a different
role in the different stages of olanzapine-induced obesity?

Olanzapine‘s activation of AMPK is significantly linked to its antagonistic effect on
the H1 receptors in the hypothalamus (Chapter 3). However, it is not known whether
the effect of olanzapine on the DVC AMPK signaling is also linked to the antagonism
of the central H1 receptors. The present study provides evidence for the first time that
olanzapine treatment activates the AMPK signaling in the DVC in a time-dependent
manner, and this effect is related to olanzapine-induced weight gain. Furthermore, we
tested whether the DVC AMPK activation could be modulated by central H1 receptor
activation and its relationship with olanzapine-induced hyperphagia.

4.2 Materials and methods

4.2.1 Animals, drugs treatment and tissue preparation
To investigate the role of DVC AMPK signaling and H1 receptors at different stages
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of olanzapine-induced weight gain, the changes in the DVC AMPK signaling and H1
receptors under olanzapine treatment for 8, 16 and 36 days have been investigated.
Additionally, whether central activation of H1 receptor inhibits olanzapine-induced
changes in DVC AMPK has been examined. The same rats, olanzapine treatment
procedures and FMPH treatment (icv experiment) described in Chapter 2 and 3 were
used in the present study. The DVC nuclei were immediately dissected on ice, frozen
in liquid nitrogen and then stored at -80°C.

4.2.2 Western blot
The protein expression of the H1 receptor, AMPK, pAMPKα, ACC, pACCα was
detected by western blot. Western blot was performed following the procedure
previously described in Chapter 3.

4.2.3 Statistics
Statistical analysis was performed using the SPSS 19.0 program (Chicago, IL, USA).
The differences in the H1 receptor, AMPKα, ACC, pAMPKα and pACCα protein
expression after 8, 16 and 36 days olanzapine or vehicle treatments were analyzed
using an independent unpaired student t-test (two-tailed). In the icv experiment, the
statistical differences of pAMPKα and pACCα expression were analyzed by one-way
ANOVA followed by post hoc Tukey‘s multiple comparison in the DVC. Correlations
were identified using Pearson‘s correlation. All data were presented as mean ± SEM.
Statistical significance was defined as p < 0.05.
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4.3 Results

4.3.1. Olanzapine activated the DVC AMPK signaling after 8 days but not 16 or
36 days treatment
Since the DVC AMPK plays an important role in feeding and body weight regulation
(Hayes et al., 2009, Hayes et al., 2011), the time-dependent effects of olanzapine on
DVC AMPK signaling has been investigated by treating rats with olanzapine for 8, 16
and 36 days. After the 8-day olanzapine treatment when the rats were hyperpahgic,
the protein expression of pAMPKα and its directly downstream pACCα were
significantly increased (120 ± 6%, p = 0.030; 121 ± 5%, p = 0.022 vs. control,
respectively, Figure 4.1A,B) without changes been seen in total AMPKα and ACC
expression (p > 0.05) compared with control. Persons correlation revealed that the
ratio of pAMPK/AMPK (an indicator of AMPK activity) was significantly correlated
with cumulative food intake (r =0.714, p = 0.014, Figure 4.1C), weight gain (r =
0.685, p = 0.020, Figure 4.1D) and feeding efficiency (r = 0.615, p = 0.044, Figure
4.1E). These findings suggest that DVC AMPK signaling may be associated with
olanzapine-induced hyperphagia and weight gain. After the 16 or 36-day olanzapine
treatments, the protein expressions of AMPKα, pAMPKα, ACC, and pACCα in the
DVC were not significantly altered (Figure 4.2A-D), suggesting that the DVC AMPK
signaling may play a time-dependent role in olanzapine-induced weight gain. Persons‘
correlation revealed that the pAMPKα expression was positively correlated with the
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last 48 h food intake (16-day: r =0.639, p = 0.034; 36-day: r =0.655, p = 0.040, Figure
4.2E, F), suggesting that during long-term olanzapine treatment (16 and 36 days), loss
of AMPK may explain at least partially why olanzapine did not increase food intake
during chronic treatment.

Figure 4.1 Effects of olanzapine on the protein expressions of DVC AMPK signaling
and the H1 receptor after 8 days olanzapine treatment (n =5- 6/group). A, The protein
expression of the DVC H1 receptor, AMPKα, pAMPKα, ACC and pACCα after 8
days olanzapine or vehicle treatment. B, Western blot bands of representative DVC
samples of rats treated with olanzapine or vehicle for 8 days displaying bands of the
H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression in the DVC. C,
D, and E, Correlations within the DVC pAMPK/AMPK activity, food intake, weight
gain and feeding efficiency after 8 days treatment of olanzapine or vehicle. All data
are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* p <
0.05 vs. control). Abbreviations: DVC: dorsal vagal complex.
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In the central nervous system, a previous study (Kim et al., 2007) and findings
presented in Chapter 3 of the present thesis have shown that the antipsychotic-induced
activation of AMPK is related to its antagonistic effect on the histamine H1 receptors,
in particular clozapine and olanzapine. Olanzapine has affinity for a range of
receptors. Olanzapine‘s antagonistic effect on the H1 receptors appears to mediate
olanzapine-induced weight gain (Matsui-Sakata et al., 2005), via the regulation of
AMPK signaling (Kim et al., 2007). Therefore we examined the time-dependent
effect of olanzapine on the expression of the DVC H1 receptor, and its relationship
with DVC AMPK signaling. Western blot was performed to detect the protein
expression of H1 the receptors. The expression of the DVC H1 receptor was not
significantly altered by the 8-, 16-, and 36-day olanzapine treatments (Figure 4.1 A,B;
4.2A-D). However, the DVC H1 receptor expression was significantly positively
correlated with DVC pAMPKα expression in all the 3 experiments (8-day: r = 0.760,
p = 0.011; 16-day: r = 0.671, p = 0.034; 36-day: r = 0.685, p = 0.020, respectively).
These correlations suggest that although the DVC H1 receptor protein expression was
not significantly altered, it may be related to DVC AMPK signaling.
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Figure 4.2 Effects of olanzapine on the protein expressions of DVC AMPK signaling
and the H1 receptor after 16 and 36 days olanzapine treatment (n = 5-6/group). A,
Western blot bands of representative DVC samples of rats treated with olanzapine or
vehicle for 16 days. B, The protein expression of the DVC H1 receptor, AMPKα,
pAMPKα, ACC and pACCα after 16 days treatment of olanzapine or vehicle. C, ,
Western blot bands of representative DVC samples of rats treated with olanzapine or
vehicle for 16 days for 36 days. D, The protein expression of DVC H1 receptor,
AMPKα, pAMPKα, ACC and pACCα after 36 days treatment. E and F, Correlations
between the DVC pAMPK and last 48 h food intake after 16 and 36 days treatment.
All data are presented as mean ± SEM. Statistical significance was defined as p <
0.05.
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4.3.2. Olanzapine-induced activated DVC AMPK was inhibited by the H1
receptor agonist in a dose-dependent manner
We further investigated whether olanzapine‘s effect on the DVC AMPK is associated
with its antagonistic effect on the H1 receptors, and whether this effect is related to
olanzapine-induced hyperphagia. Olanzapine-treated rats were given a central
injection of different doses of the H1 receptor agonist, FMPH, as described in Chapter
3. Icv injection of FMPH significantly reduced olanzapine-induced elevation of food
intake in a dose- and time-dependent manner (Chapter 3).

In terms of DVC AMPK signaling, the data revealed significantly increased pAMPKα
(135 ± 5% vs. vehicle/saline) and pACCα (134 ± 7% vs. vehicle/saline) expression
after 5 days of olanzapine treatment (Figure 4.3 A, B; ANOVA, F(5,31) = 11.057, p =
0.000; F(5,28) = 5.988, p = 0.001, respectively, n = 5-7/group, Tukey post hoc tests).
This stimulatory effect of olanzapine on DVC pAMPKα was inhibited by 200 nmoles
FMPH (109 ± 5%, p = 0.013; Tukey post hoc tests), but not by 100 nmoles FMPH
compared to saline (124 ± 3%, p > 0.05, Tukey post hoc tests). 200 nmoles FMPH
also tended to inhibit pACCα expression (109 ± 4%, p = 0.078, Tukey post hoc tests)
compared to saline. Pyrilamine treatment reversed the inhibitory effect of 200 nmoles
FMPH on pAMPKα and pACCα expression following the olanzapine treatment (141
± 12%, p = 0.000; 136 ± 7%, p = 0.037, Tukey post hoc tests). An icv injection of
FMPH on vehicle-treated rats did not significantly alter the DVC pAMPKα and
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pACCα levels. Moreover, the DVC pAMPKα expression was also positively
correlated with food intake at 1 h (Figure 4.3 C). These findings indicate that the
DVC AMPK appears to regulate olanzapine-induced hyperphagia and weight gain,
and this effect is linked to olanzapine‘s antagonistic effect on the central H1 receptors.

Figure 4.3 Effects of an acute central injection of the H1 receptor agonist, 2-(3trifluoromethylphenyl) histamine (FMPH), on DVC AMPK signaling (n = 5-8/group).
A Representative western blot bands of pAMPKα and pACCα receptor expression in
the DVC of the olanzapine or vehicle-treated rats receiving the icv injection of FMPH
or saline. B, Effects of the H1 receptor agonist, FMPH, on the DVC pAMPK and
pACC expression in olanzapine or vehicle-treated rats. C, Correlation between
pAMPK expression and food intake 1 h after the last drug treatment. All data are
presented as mean ± SEM. Statistical significance was defined as p < 0.05 (* p < 0.05,
** p < 0.01). H, high dose; L: low dose; PY: pyrilamine; V/S, vehicle/saline; V/F(H),
vehicle/FMPH 200 nmoles; O/S, olanzapine/saline; O/F(L), olanzapine/FMPH 100
nmoles; O/F(H), olanzapine/FMPH 200 nmoles; O/F(H)/PY, olanzapine/FMPH 200
nmoles/pyrilamine 800 nmoles.
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4.4 Discussion
The present study provides the first evidence that olanzapine treatment timedependently affects DVC AMPK signaling. Rats treated with olanzapine for 8 days
have significantly activated DVC AMPK signaling. However this DVC AMPK
activation disappeared with prolonged olanzapine treatment (16 and 36 days). During
short-term olanzapine treatment (< 12 days), the rats had an elevated food intake and
rapid weight gain, consistent with previous studies (Albaugh et al., 2006, Huang et al.,
2006, Stefanidis et al., 2008, van der Zwaal et al., 2012). The significant correlation
between DVC AMPK activity and food intake, weight gain and feeding efficiency
suggest that DVC AMPK signaling may significantly contribute to the olanzapineinduced hyperphagia and weight gain during this period. As treatment was prolonged,
olanzapine no longer induced an elevated food intake (3-5 weeks), however a higher
body weight was maintained compared to the control animals in both the current
study and other studies (Albaugh et al., 2006, Huang et al., 2006, Stefanidis et al.,
2008). Consistently, with food intake, long-term olanzapine treatment did not
significantly activate DVC AMPK signaling, and pAMPK expression was positively
correlated with the last 48 h food intake. These data suggest that during long-term
olanzapine treatment, the disappearance of the DVC AMPK activation may partly
explain why long term-olanzapine treatment (>2 weeks) no longer induced
hyperphagia.

In addition to regulating food intake, the fact that the rats gain weight without
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hyperphagia suggests that other factors are involved in olanzapine-induced weight
gain. In the clinic, for example, decreased energy expenditure has been reported to be
involved in weight gain induced by olanzapine and clozapine treatment (Sharpe et al.,
2005, Sharpe et al., 2006, Cuerda et al., 2011). Previous studies in animal models also
show that SGAs (including olanzapine and clozapine) decreased energy expenditure
by inhibiting sympathetic activity in the brown adipose tissue (Blessing et al., 2006,
Skouroliakou et al., 2009, van der Zwaal et al., 2012). Moreover, data from our group
has found that chronic olanzapine treatment (36-day) is associated with decreased
temperature in BAT, accompanied by decreased BAT UCP-1 expression and PGC-1α
expression, which are important markers of BAT thermogenesis (Zhang et al., 2014b).
DVC AMPK signaling has also been shown to be involved in regulating energy
expenditure via its regulation of heart rate (Hayes et al., 2009). However the role of
DVC AMPK in BAT thermogenesis has not been fully studied. In this study, DVC
AMPK was activated by olanzapine after the 8-day treatment but not the 16 or 36-day
treatments. These changes in DVC AMPK do not match the changes in BAT
temperature and UCP-1 and PGC α expression. This evidence suggests that the
decreased BAT temperature after chronic olanzapine treatment could be due to
reduced sympathetic activity on BAT. This effect occurs independently of
olanzapine‘s effect on DVC AMPK signaling. Mechanisms besides AMPK may be
involved in olanzapine-induced weight gain, for example NPY and POMC (Ferno et
al., 2011).
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The mechanism by which olanzapine activates DVC AMPK signaling has also been
investigated. Olanzapine has a high affinity for the H1 receptors, which is one of the
major contributors to olanzapine-induced weight gain. Previous evidence has
demonstrated that the NTS within the DVC is heavily innervated by the hypothalamic
histaminergic projections (Watanabe et al., 1984, Bhuiyan et al., 2011). The NTS
contains abundant H1 receptors which are predominantly located on neurons
(Bhuiyan et al., 2011). It has been reported in rats that the NTS H1 receptor activation
increases arterial pressure and heart rate (Bhuiyan et al., 2011). However, the role of
the DVC H1 receptors in the regulation of food intake is unknown. This study
demonstrated that central H1 receptor activation inhibited the hyperphagia and DVC
AMPK activation induced by olanzapine, and the pAMPK expression was correlated
with food intake. Therefore, it is possible that the antagonism of the DVC H1
receptors by olanzapine may contribute to the activation of AMPK in the DVC and
increased food intake.

The cross-communication of the DVC and hypothalamic pathways in regulating food
intake and energy balance has already been studied (Blevins and Baskin, 2010). The
DVC receives projections from the hypothalamus in the regulation of food intake
(Blevins and Baskin, 2010). In this study, the H1 receptor agonist was injected into
the lateral ventricle (easy access to the hypothalamus). Thus, the inhibitory effect of
the H1 receptor agonist on DVC AMPK signaling could also be an indirect effect
caused by the hypothalamus. In Chapter 3 it was reported that olanzapine (3 mg/kg)
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significantly activated hypothalamic AMPK after the 8-day treatment. This change is
consistent with the change in DVC AMPK signaling. However correlation analyses
have shown that pAMPK expression in the hypothalamus and the DVC are not
correlated. With prolonged olanzapine treatment, the hypothalamic AMPK was not
activated after the 16-day treatment, and was actually inhibited after the 36-day
treatment. These changes in DVC AMPK signaling are not consistent with the
changes in AMPK in the hypothalamus. The inconsistency suggests that the
hypothalamic and DVC AMPK may be mediated via independent mechanisms. In
fact, previous research has reported the difference in controlling meal size by
hypothalamus and DVC (Blouet and Schwartz, 2012). The activation of DVC AMPK
signaling after the 8-day olanzapine treatment may be directly caused by olanzapine‘s
action on the DVC H1 receptors but not a secondary effect of the hypothalamus. DVC
neurons integrate multiple neuropeptides and signals from the forebrain, integrate gut
and adiposity signals for long-term energy storage and determine food intake
(Schwartz, 2006). As DVC AMPK is an energy sensor which responds to energy
status (Hayes et al., 2009), the inactivation of AMPK during long-term olanzapine
treatment may be caused by a negative response to energy overload. Moreover, it has
been reported that chronic olanzapine (≥ 14 days) treatment in rats did not change
ghrelin (Zhang et al., 2014a), DVC NPY and POMC expression (Weston-Green et al.,
2012) which are all important regulators of AMPK. It is possible that the lack of DVC
AMPK activation after chronic olanzapine treatment may be affected by multiple
parameters besides the H1 receptors, such as ghrelin, NPY or POMC. Further studies
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are needed. It would be helpful to identify the neurochemical phenotype of neurons in
the DVC that express AMPK. In addition, it would be desirable to test whether the
direct activation of the DVC H1 receptors blocks the olanzapine-induced weight gain
and AMPK activation. Previous studies have also reported that the G-protein coupled
receptors including the H1 receptors can be desensitized following a continuous
activation by receptor agonists (Bristow and Zamani, 1993, Pype et al., 1998, Woolf
and Linderman, 2003). There are some exceptions to this, since the serotonin 2A
receptor can be desensitized by both agonist and antagonist exposure. Chronic
olanzapine treatment causes the desensitization of serotonin 2A receptor signaling and
the down-regulation of serotonin 2A receptor expression (Hanley and Hensler, 2002,
Singh et al., 2010). Olanzapine is an H1 receptor antagonist. However, there is no
evidence to suggest that olanzapine treatment or other H1 receptor antagonists lead to
the desensitization of H1 receptor signaling. In the present study, H1 receptor
expression is not changed by chronic olanzapine treatment, indicating that a
desensitization effect is unlikely.

4.5 Summary
In conclusion, the present study demonstrates that the effect of olanzapine on DVC
AMPK signaling varies during different treatment periods. After short-term treatment
(8 days), olanzapine activated AMPK signaling, which may contribute to olanzapineinduced hyperphagia. With prolonged treatment, the DVC AMPK was not
significantly activated, and the rats gained weight even without excessive food intake,
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suggesting that other parameters besides hyperphagia and DVC AMPK contribute to
increased body weight. Central H1 receptor activation blocks DVC AMPK activation,
suggesting that the antagonistic effects of olanzapine on the H1 receptor may be
responsible for the activation of DVC AMPK.
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CHAPTER 5

ACUTE OLANZAPINE TREATMENT IMMEDIATELY ACTIVATS AMPK
SIGNALING IN THE MBH AND BRAINSTEM DVC VIA BLOCKING
HISTAMINE H1 RECEPTOR

5.1 Introduction
In Chapter 2-4, it has been found that olanzapine-induced changes in food intake and
H1 receptor-AMPK signaling occur only in the early stage of olanzapine-induced
obesity. But the question is: what has happened to the hypothalamic and DVC H1
receptor-AMPK signaling during the first week of olanzapine treatment to cause
hyperphagia. In this study, the acute effect of olanzapine treatment on the central
AMPK signaling has been examined by intramuscular (IM) injection of the rapidacting formulation of olanzapine in rats.

Several symptoms of psychiatric illnesses rapidly develop, and sufferers may not have
access to or may refuse to take antipsychotic agents in these cases (Meehan et al.,
2002, Fukami et al., 2012). These symptoms have increased the emergency needs for
a rapid olanzapine treatment. The rapid-acting intramuscular formulation of
olanzapine offers a way which is more advantage than the oral olanzapine formulation
since it has faster onset of effect and helps patients who cannot or will not accept oral
treatment (Meehan et al., 2002). This formulation of olanzapine achieves rapid plasma
concentrations for therapeutic effect and fast to treat agitation associated with bipolar
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mania and schizophrenia (Wagstaff et al., 2005). Therefore, this formulation of
olanzapine is suitable for examining the acute effect of olanzapine on the H1 receptorAMPK signaling in the hypothalamus and brainstem DVC. In this study, olanzapine
was injected once (one injection) and 9 times (3 injections/day over 3 days) at a
dosage of 1mg/kg. Associations between changes in H1 receptor-AMPK signaling
and food intake and weight gain were also studied.

5.2 Martials and methods

5.2.1 Animals and housing
Female SD rats (weight 200-225g) were obtained from the Animal Resources Centre
(Perth, WA, Australia). The rats were housed under an environmentally controlled
condition (22°C on a 12h light-dark cycle (lights on 0700 h)). Rats were allowed ad
libitum access to food and water throughout the studies. All animal experimental were
approved by the Animal Ethics Committee, University of Wollongong, and complied
with the Australian Code of Practice for the Care and Use of Animals for Scientific
Purposes (2004).

5.2.2 Acute olanzapine treatment and tissue dissection
After acclimatization, rats (12 weeks old) were injected intramuscularly with
olanzapine or water as a control for one injection and 9 injections (1 mg/kg, 3
times/day, 3 days in total, n = 6/group). Cumulative food intake and weight gain were
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measured. At the end of treatment, all rats were euthanized by CO2 asphyxiation 2 h
after the last drug treatment between 0900 h to 1100 h. The rat brain was quickly
collected. The DVC was quickly dissected on ice and frozen in liquid nitrogen and
then stored at -80 °C. The hypothalamic nuclei (MBH and PVN) were identified and
dissected using the same procedure described in Chapter 3.

5.2.3 Western blot
Western blot was used to examining the protein expression of H1 receptor, AMPKα
pAMPKα, ACC and pACCα in the MBH, PVN and brainstem DVC. The standard
procedure has been described in Chapter 3.

5.2.4 Statistics
The statistics were performed by the SPSS 19.0 program (Chicago, IL, USA). Twoway analysis of variance (ANOVA) (olanzapine × time as repeated measure) was used
to analyse the statistical differences in cumulative food intake and weight gain
between olanzapine and control groups The differences in the protein expression of
H1 receptor, AMPKα, ACC, pAMPKα and pACCα between olanzapine and control
group were analysed using an independent unpaired student t-test (two-tailed).
Correlations were identified using Pearson‘s correlation. All data were presented as
mean ± SEM. Statistical significance was defined as p < 0.05.
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5.3 Results

5.3.1 IM injection of olanzapine-induced food intake and weight gain
Compared with control group, olanzapine-treated group had a significantly elevated
accumulative food intake and weight gain after 9 injections (day 3) (by 19%, p =
0.009, by 241%, p = 0.009, respectively, n = 6/group) but not one injection (Figure
5.1A-C). Feeding efficiency was also significantly increased after 9 injections (3
days) (by 164%, p = 0.025, n = 6/group, Student‘s t test, Figure 5.1D).

5.3.2 The effect of olanzapine on AMPK signaling in the MBH, PVN and
brainstem DVC
Increased pAMPK/AMPK ratio is an important indicator of AMPK activation and has
been used in numerous studies (Dzeja et al., 2011, Fukami et al., 2012, Chapnik et al.,
2014). In the present study, in the MBH, a single injection of olanzapine nonsignificantly increased the pAMPK/AMPK ratio (by 16%, p = 0.07 vs. control, n =
6/group, Student‘s t test) and induced a small but statistically significant increase of
pACC/ACC ratio (by 10%, p = 0.010) (Figure 5.2A, D). However, in the PVN, both
the pAMPK/AMPK and pACC/ACC ratio were not significantly altered by
olanzapine (p = 0.861, p = 0.855, respectively), consistent with the findings in
Chapter 3 (Fig.5.2B, D). In the brainstem DVC, one injection of olanzapine increased
the pAMPK/AMPK ratio and pACC/ACC ratio compared with water (control) (by
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20%, p = 0.007; 22%, p = 0.035, respectively, Figure 5.2C, D).

Figure 5.1 Food intake, weight gain and feeding efficiency in rats receiving IM
injections of olanzapine (1mg/kg, tid) or water (control) for one injection (A) and 9
injections ( 3 days, B, C, D) (n = 6/group). All data are presented as mean ± SEM.
Statistical significance was defined as p < 0.05 (* p < 0.05, ** p < 0.01 vs. control).
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Figure 5.2 Effects of IM injection of olanzapine (one injection) on the protein
expression of key components of hypothalamic H1 receptor-AMPK signaling (n =
6/group). A-C Western blots analysis of the protein expression of H1 receptor,
pAMPKα/AMPKα ratio, pACCα/ACC ratio in the MBH (A), PVN (B) and DVC (C).
D, Western blot of representative samples of olanzapine or water-treated rats, displays
bands of H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression. All
data are presented as mean ± SEM. Statistical significance was defined as p < 0.05 (*
p < 0.05, ** p < 0.01 vs. control). Abbreviations: DVC; dorsal vagal complex; MBH:
mediobasal hypothalamus; PVN: paraventricular nucleus.
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After 9 injections (3 days) of olanzapine, rats receiving olanzapine treatment became
hyperphagic and significantly gained body weight. Compared with control,
olanzapine significantly increased pAMPK/AMPK ratio in the MBH (16%, p = 0.005
vs. control, n = 6/group, Student‘s t test) but not pACC/ACC ratio (10%, p = 0.365)
(Figure 5.3A, D). Consistent with a single injection of olanzapine, olanzapine
treatment for 3 days did not induce significant alterations of pAMPK/AMPK ratio or
pACC/ACC ratio in the PVN (p = 0.362, p = 0.347, respectively, Figure 5.3B, D). The
DVC pAMPK/AMPK ratio but not pACC/ACC ratio was also significantly increased
(by 27%, p = 0.003; 13%, p = 0.138, respectively, Figure 5.3C, D). The MBH and
DVC pAMPK/AMPK ratio were positively correlated with feeding efficiency and
weight gain (Table 5.1). These findings suggest that activation of the MBH and DVC
AMPK may largely contribute to IM injection of olanzapine-induced hyperphagia and
weight gain.

Olanzapine‘s activation of AMPK has been proved to be related to its antagonistic
effect on the H1 receptors (Chapter 3 and 4). The protein expression of hypothalamic
and DVC H1 receptor has been examined by western blot. The H1 receptor protein
expression in the MBH and DVC was not significantly altered by acute IM injection
of olanzapine (all p > 0.05, Figure 5.2 – 5.3). However, in all the experimental
cohorts, H1 receptor expression positively correlated, or trended towards positive
correlation, with pAMPK expression (r ≥ 0.572, p ≤ 0.066), suggesting that AMPK
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activation is significantly related to the H1 receptor.

Table 5.1 Correlations within the pAMPK/AMPK ratio in the MBH and DVC,
feeding efficiency and cumulative weight gain after rats received 9 injections (3 days)
of olanzapine or water as a control.

9 injections

Feeding efficiency

Weight gain

(3 days)

r (P-value)

r (P-value)

pAMPKα/AMPK

0.810 (0.008**)

0.787(0.012*)

Weight gain

0.981 (0.000**)

pAMPKα/AMPK

0.736(0.024*)

Weight gain

0.981(0.000**)

MBH

DVC

0. 796(0.010*)

Abbreviations: AMPK: AMP-activated protein kinase; DVC: dorsal vagal complex;
MBH: mediobasal hypothalamus; pAMPKα: AMPK phosphorylated Thr172 at
AMPKα subunits. Statistical significance was defined as p < 0.05 (* p < 0.05, ** p <
0.01). Significant correlations are indicated in bold.
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Figure 5.3 Effects of IM injection of olanzapine (9 injections) on the protein
expression of key components of hypothalamic H1 receptor-AMPK signaling (n =
6/group). A-C Western blots analysis of the protein expression of H1 receptor,
pAMPKα/AMPKα ratio, pACCα/ACC ratio in the MBH (A), PVN (B) and DVC (C).
D, Western blot of representative samples of olanzapine or water-treated rats, displays
bands of H1 receptor, AMPKα, pAMPKα, ACC, pACCα and actin expression.
Abbreviations: DVC; dorsal vagal complex; MBH: mediobasal hypothalamus; PVN:
paraventricular nucleus.
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5.4 Discussion
In the clinic, increased food intake is an important factor that causes weight gain in
patients treated with olanzapine and clozapine (Theisen et al., 2003, Gebhardt et al.,
2007). In animal models, both the present study (Chapter 2) and other studies
(Albaugh et al., 2006, Huang et al., 2006, Stefanidis et al., 2008, van der Zwaal et al.,
2012) have shown that food intake is a main contributor to rapid weight gain during
the early stage of olanzapine-induced obesity. However olanzapine treatment did not
induce an elevation of food intake during the first day of treatment (Huang et al.,
2006, Ferno et al., 2011, Weston-Green et al., 2011). In the present study, olanzapine
only significantly increased food intake from 9 injections (day 3) but not one
injection, which is consistent with previous studies.

However the question is: how does acute olanzapine treatment cause hyperphagia.
The present study demonstrated for the first time that a single injection of olanzapine
immediately induced AMPK activation in both the hypothalamic MBH (but not in the
PVN) and brainstem DVC. Further, these effects continued after 9 injections (3 days)
of olanzapine. The MBH contains the Arc and VMH which are important in the
regulation of food intake and body weight (Blouet et al., 2009). As discussed in
Chapter 1, AMPK in the MBH and DVC regulates food intake, energy expenditure
and body weight (Xue and Kahn, 2006, Schneeberger and Claret, 2012). Therefore,
olanzapine-induced AMPK activation in the MBH and DVC may largely contribute to
IM injection of olanzapine-induced increased food intake and feeding efficiency.
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In the present study, after one IM injection of olanzapine, the DVC pAMPK/AMPK
ratio significantly increased, and the MBH pAMPK/AMPK ratio tended to increase.
These data suggest that IM injection of olanzapine-induced activation of central
AMPK signaling onsets immediately after the first treatment and before the increase
of food intake. When rats were treated with olanzapine for 3 days (9 injections), rats
had a significantly increased food intake, accompanied by activated AMPK signaling
in the MBH and brainstem DVC. The MBH and DVC pAMPK/AMPK ratio
positively correlated with feeding efficiency and weight gain, supporting the
statement that activation of the hypothalamic and DVC AMPK contributes to IM
injection of olanzapine-induced elevation of food intake. Moreover, activation of the
hypothalamic and DVC AMPK signaling was from one injection and still continued
after 9 injections suggest that a sustained activation of the hypothalamic and DVC
AMPK signaling is required for olanzapine-induced increased food intake during
short-term treatment.

H1 receptors in the MBH are involved in regulating food intake (Fukagawa et al.,
1989, Umehara et al., 2010). Clozapine activates the hypothalamic AMPK by
blocking H1 receptors (Kim et al., 2007). Olanzapine activates the central AMPK
signaling via blocking in the H1 receptors (Chapter 3 and 4). In the current study,
pAMPK expression significantly positively correlated with H1 receptor expression.
The data support the concept that olanzapine activates the central AMPK via H1
receptor blockade. During the early stage of olanzapine-induced weight gain, H1
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receptor-AMPK signaling in the hypothalamic-brainstem circuits plays an essential
role in olanzapine-induced hyperpahgia and rapid weight gain.

5.5 Summary
In conclusion, acute IM injection of olanzapine treatment immediately induced an
activation of the MBH and DVC AMPK signaling via blockade of the H1 receptor.
This sustained activation of AMPK is an important factor that causes elevated food
intake after 9 injections (3 days) of olanzapine. Therefore, a sustained inhibition of
AMPK signaling in both the hypothalamus and brainstem DVC from the first
treatment of olanzapine may be effective for protecting patients from hyperphagia and
gaining weight, and further studies are needed.
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CHAPTER 6

OVERALL DISCUSSION AND CONCLUSIONS

6.1 Overall discussion
The present series of studies demonstrated a time-dependent role of the brain
histaminergic system and its associated AMPK signaling in the progressive
development of olanzapine-induced obesity (illustrated in Figure 6.1). The study
firstly reported that in female rats olanzapine (1 mg/kg/day, tid, oral) induced obesity
in a pattern that significantly mimicked the olanzapine-induced obesity in the clinic
(Pai et al., 2012): In the early stage, olanzapine treatment led to hyperphagia and
rapidly increase in body weight (day 1-12); in the middle stage, the rats were no
longer hyperphagic and the ratio of weight gain slowed down (during day 13-28), and
in the late stage (day 29-36), weight gain plateaued and the high body weight was
maintained with continuous olanzapine treatment. These findings suggest that
different neural mechanisms may be responsible for the weight gain development and
maintenance in the three stages of olanzapine-induced obesity. Increased food intake
only contributes to weight gain at the early stage. As discussed in Chapter 1, several
lines of evidence point to a critical role for the brain histaminergic system in the
regulation of food intake and body weight, in particular the H1 receptor, HDC and H3
receptor (Fulop et al., 2003, Masaki and Yoshimatsu, 2006, Passani et al., 2011).
Olanzapine has a high affinity for the H1 receptor. H1 receptor affinity predicts shortterm SGA-induced weight gain (Kroeze et al., 2003). In Chapter 2, it was reported for
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the first time that central H1 receptor binding was increased by olanzapine not only in
the hypothalamic Arc and VMH but also in the brainstem DVC in the three stages of
olanzapine-induced weight gain. Importantly, changes in H1 receptor binding
positively correlated with feeding efficiency and weight gain. These data suggest that
the H1 receptor blockade contributes to olanzapine-induced weight gain not only in
the early but also in the middle and late stages of obesity development. Central H1
receptor blockade increases food intake (Sakata et al., 1988, Ookuma et al., 1989) and
decreases energy expenditure，partly by regulating the sympathetic outflow to BAT
(Masaki et al., 2001, Masaki et al., 2004). Findings from the present series of
experiments suggest that in the early stage of olanzapine-induced obesity, the H1
receptor antagonism by olanzapine in these regions contributes to olanzapine-induced
rapid weight gain by increasing food intake. As treatment is prolonged (middle and
late stage), antagonism of the H1 receptors leads to weight gain and the maintenance
of high body weight by decreasing BAT thermogenesis (He et al., 2014). Moreover,
we have reported here for the first time that olanzapine treatment leads to a
compensatory increase in the hypothalamic HDC mRNA expression in the early stage
of olanzapine-induced obesity. The HDC mRNA expression was correlated with food
intake, weight gain and feeding efficiency. However, changes in HDC mRNA
expression vanished at the middle and late stages of olanzapine-induced obesity (the
rats were not hyperphagic). These findings indicate the significant association of HDC
with olanzapine-induced hyperphagia in the early stage. During chronic olanzapine
treatment, the histamine tone may also be affected by other mechanisms such as the
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serotonin 2A receptor blockade by olanzapine (Morisset et al., 1999). Although
olanzapine has a low affinity for the H3 receptors, olanzapine non-significantly
decrease H3 receptor binding in the Arc at the late stage of obesity development. H3
receptor binding density was negatively correlated with olanzapine-induced weight
gain. Target disruption of H3 receptors results in reduced energy expenditure and
obesity (Takahashi et al., 2002). Our findings suggest that long-term olanzapine
treatment also deceases energy expenditure and maintain high body weight via
indirectly affect the H3 receptors in the Arc.

Having demonstrated the critical role of H1 receptor in the hypothalamus and DVC in
olanzapine-induced obesity (Chapter 2), the key question is what are the intracellular
mechanisms associated with H1 receptor blockade to cause weight gain at each stage.
According to the literature, the best target of H1 receptor I hypothesis is AMPK. The
data in Chapter 3 and 4 reported that the hypothalamic and DVC AMPK signaling
were time-dependently affected in response to olanzapine treatment and were related
to olanzpane-induced weight gain. At the early stage, when the rats were hyperphagic,
the AMPK in the hypothalamus and DVC were activated due to H1 receptor blockade
by olanzapine, and this effect leads to hyperphagia, and thus causes rapid weight gain.
During chronic olanzapine treatment, when the rats were no longer hyperphagic
however weight gain persisted, olanzapine-induced weight gain was driven by other
factors such as decreased energy expenditure (Stefanidis et al., 2008, Zhang et al.,
2014b). The present study found that AMPK signaling was no longer activated at the
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middle and late stages of olanzapine-induced obesity. This indicated olanzapineinduced decrease in BAT thermogenesis can occur independently of its effect on
central AMPK signaling. Antagonism of the H1 receptor by olanzapine may cause
decreased energy expenditure via other pathways that are linked to metabolic
regulation, for example the NPY and AgRP (Ferno et al., 2011). Since AMPK is an
energy sensor, AMPK may be inhibited via a feedback mechanism of energy over
load and high body weight (Ferno et al., 2011), or other mechanisms still unknown
during chronic olanzapine treatment.

The involvement of the hypothalamic and DVC AMPK activation in the early stage of
olanzapine-induced hyperphagia and weight gain stimulates many questions: Are the
effects of olanzapine on the central AMPK signaling due to central actions of
olanzapine? Are these effects directly related to blockade of central H1 receptor?
Olanzapine is an H1 receptor antagonist and blocks H1 receptors, therefore we
examined whether central activation of H1 receptor could block olanzapine-induced
hyperphagia and AMPK activation. Our investigation shows that central H1 receptor
activation by a selective H1 receptor agonist, FMPH, dose- and time-dependently
reduced olanzapine-induced food intake and inhibited AMPK activation in the
hypothalamic MBH and brainstem DVC. pAMPK expression in the two regions was
correlated with food intake. These findings support the concept that changes in
AMPK signaling induced by olanzapine are due to olanzapine‘s direct action on the
central H1 receptors. Moreover, lowering the AMPK signaling via activating central
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H1 receptor is an effective treatment for olanzapine-induced hyperphagia associated
with obesity development.

Following the demonstration in Chapter 2-4 that olanzapine-induced changes in food
intake and H1 receptor-AMPK signaling occur only in the early stage of olanzapineinduced obesity, we were interested to investigate what happened to the hypothalamic
and DVC H1 receptor-AMPK signaling during the first week of olanzapine treatment.
However, what has happened to the hypothalamic and DVC H1 receptor-AMPK
signaling during the first week of olanzapine treatment? Chapter 5 reported that
olanzapine immediately activates the hypothalamic and DVC AMPK signaling via
blockade of the H1 receptors. This activation continues on day 3 when food intake
starts to increase. These findings support the statement that a sustained AMPK
activation via H1 receptor blockade from the first treatment in the hypothalamus and
DVC is required for olanzapine to cause hyperphagia, and thus leads to rapid weight
gain during the early stage of obesity development.

Taken together, this thesis reveals that the progressive development of olanzapineinduced obesity involves different neural mechanisms at each stage. The
histaminergic system plays an important and time-dependent role in olanzapineinduced obesity. At the early stage, H1 receptor antagonism by olanzapine
immediately leads to an activation of the downstream AMPK signaling in both the
MBH and brainstem DVC. A sustained AMPK activation causes hyperphagia and
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rapid weight gain (Figure 6.1). With a prolonged treatment, rats are no longer
hyperphagic however gain more weight at a lower rate (middle stage), and maintain a
high body weight in the late stage. AMPK working as an energy sensor may be
inhibited by positive energy balance induced by olanzapine. The rats gain more
weight although the excessive food intake is no longer present; suggesting that other
parameters in addition to hyperphagia and AMPK may contribute to increased body
weight. Antagonism of the H1 receptors may contribute to weight gain and high body
weight maintenance via decreasing energy expenditure (He et al., 2014). Moreover,
olanzapine treatment caused an increase in the hypothalamic HDC but decease in the
H3 receptor binding. These effects may favour weight gain during olanzapine
treatment. Nevertheless, this thesis contributes to understanding the neural
mechanisms underlying the different stages of olanzapine-induced weight gain, and
may shed light on the prevention and treatment of olanzapine-induced weight gain via
regulation of the central histamine system.

6.2 Recommendations for further research
(1) Central HDC and H3 receptor, which control histamine synthesis and release,
play a time-dependent role in olanzapine-induced weight gain; however the
mechanisms are still not fully understood. Further studies that investigate the
hypothalamic histamine release and its relationship with changes in HDC, H3
receptor and olanzapine‘s antagonistic effect on the H1 receptor in different
stages of olanzapine-induced obesity would be helpful to understand how
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olanzapine modulates the histaminerigc system in different stages.

(2) The H1 receptor plays an important role in the early, middle and late stage of
olanzapine-induced obesity. Central H1 receptor activation is effective in
reducing olanzapine-induced hyperphagia. Further studies are needed to
investigate the effect of long-term activation of central H1 receptor in reducing
olanzapine-induced weight gain, and how does it influence the key
components that regulate food intake (including AMPK, NPY, POMC, AgRP,
and cocaine and amphetamine-regulated transcript) and energy expenditure
(including makers of BAT thermogenesis such as PGC-1α and UCP-1), as well
as locomotor activity.

(3) In the clinic, a number of patients treated with olanzapine are associated with
established obesity. To investigate whether central H1 receptor activation is
able to attenuate rats with established obesity induced by olanzapine treatment
is warranted.

(4) In the present study, AMPK in the hypothalamic and brainstem DVC has been
identified as an important contributor in olanzapine-induced hyperphagia. It
would be helpful to further investigate whether inhibition of the hypothalamic
and DVC AMPK could inhibit olanzapine-induced hyperphagia and obesity.
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Figure 6.1 A potential mechanism of the histaminergic system and its associated AMPK signaling in different stages of olanzapine-induced
obesity.
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Olanzapine has a high affinity for the H1 receptor in the histamine system. (A) In terms of the histaminergic system: In the early stage of
olanzapine-induced obesity, H1 receptor antagonism by olanzapine in the hypothalamus results in an impaired central histamine system
including an increased H1 receptor binding density in the hypothalamic Arc and VMH, as well as an increased hypothalamic HDC mRNA
expression. These effects trigger olanzapine-induced food intake and weight gain. (B) In terms of the intracellular mechanisms of H1
receptor: By antagonism of the H1 receptors, olanzapine treatment immediately activates the AMPK signaling in the hypothalamic MBH and
brainstem DVC. The sustained activation of AMPK signaling in the MBH and DVC results in hyperphagia, and thus causes rapid weight gain.
As treatment is prolonged (in the middle and late stage), AMPK, which works as an energy sensor, negatively responds to the positive energy
balance induced by olanzapine treatment. At these stages, H1 receptor antagonism contributes to olanzapine-induced weight gain and high body
weight maintenance via deceasing energy expenditure. Abbreviations: AMPK: AMP-activated protein kinase; DVC: dorsal vagal complex; FI:
food intake; H1R: H1 receptor; H3R: H3 receptor; HA neuron: histamine neuron; HDC: histidine decarboxylase; MBH: mediobasal
hypothalamus; WG: weight gain.
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APPENDIX TWO
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Olanzapine-activated AMPK signaling in the dorsal vagal complex is attenuated by
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